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ABSTRACT 
 
   A drug compound is most commonly introduced into the systemic plasma circulation by means of a 
solid oral dosage form due to convenience, robustness and ease of product handling. The utilisation of 
preparations that release their contents slowly in the gastrointestinal tract, i.e. prolonged release 
preparations, can reduce several undesired effects, such as unnecessarily frequent administration, 
unwanted side-effects or local irritation. However, the development of a well-designed prolonged drug 
release preparation is a challenging task. 
   The objective of the study was to find suitable methods to control the structure and subsequent drug 
release properties of hydrophobic starch acetate (ds 2.7) matrix tablets, and to relate the structural 
properties with the drug release behaviour. In addition, the functionality of an in vitro drug release test 
which is routinely used in order to ensure the consistency and safety of the preparation was evaluated.  
   The studies indicate that the structure of the matrix tablet can be controlled by altering the particle 
size fraction of matrix forming hydrophobic excipient or making the tablet more porous. When starch 
acetate (ds 2.7) powder with an adequately small particle size fraction is used, it can form a percolating 
network within the tablet. The consistence of a networking matrix in the tablet has a great significance. 
A networking matrix of the hydrophilic drug alone leads to immediate tablet disintegration and rapid 
drug release. Co-existing percolating networks of drug and excipient result in surface erosion and 
highly variable drug release. When the hydrophobic excipient is percolating, tablets maintain their 
shape and only crack during dissolution tests. Furthermore, when the tablet porosity of the studied SA 
particle size-hydrophilic drug (caffeine) combinations is increased over 20 %, the drug release 
determining feature changes from a relaxational component into a diffusional component. 
   In tablets where the networking matrix is composed of the hydrophobic excipient, the penetrating 
liquid weakens the internal bonds and initially this causes tablet expansion which is then transformed 
into cracking. The cracking increases the drug release rate, since the formation of a crack shortens the 
length of the diffusion path, increases the effective surface area and lowers the degree of tortuosity. 
   The structure of the tablet and parameters affecting it are crucial considering the drug release 
mechanism and rate. However, the properties of the drug compound, such as the water solubility and 
solubility rate, also contribute to the drug release mechanism and rate. However, in practice, the 
situations of the formation of the matrix and drug release can be extremely complicated and knowledge 
of maximum water solubility and dissolution rate do not describe this process adequately. The results 
indicate that although compound exhibits adequate maximum water solubility and solubility rate, other 
properties, such as the magnitude and location of hydrophilic and hydrophobic areas, can cause 
significant interactions with other excipients which might not be beneficial to drug release. These 
chemical molecular properties cannot be removed by means of traditional pharmaceutical processes 
and, thus the properties and nature of the drug compound in question need to be comprehensively 
characterized in order to fully understand and control the drug release process. 
   Finally, the results showed that USP paddle method produces relevant data describing the drug 
release of prolonged hydrophobic tablets if the preparation consists of an extremely water soluble 
compound with homogenous distribution within the matrix tablet. However, in the case of a less water 
soluble compound whose particle size distribution is wide and the consequent drug distribution is less 
homogenous, the in vitro test may not produce results which are meaningful. The obtained results 
showed that less water soluble compound clearly concentrated at the bottom edge of the tablet in 
contact with the dissolution vessel, although the poor hydrodynamic properties of the USP paddle 
method were considered to play a important part in this observation. Thus, the in vitro dissolution test 
should be chosen extremely carefully for prolonged release preparations or the existing test should be 
modified when the drug compound is not highly water soluble and the preparation is a hydrophobic 
polymer based matrix tablet. 
 
National Library of Medicine Classification: QV 778, QV 785, QV 787, QV 800, QU 83, WB 350 
Medical Subject Headings: Drug Compounding; Dosage Forms; Delayed-Action Preparations; 
Administration, Oral; Tablets; Excipients; Starch/analogs & derivatives; Solubility; Hydrophobicity; 
Particle Size; Porosity; Molecular Structure 
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ABBREVIATIONS 
 
a0 initial radial dimension of tablet 
A the total amount of drug present in the matrix per unit volume 
AC acyclovir 
AP allopurinol 
ATR attenuated total reflection 
b0 initial vertical dimension of tablet 
C concentration of solute 
C0 total amount of drug in a unit volume of the matrix 
Cs saturation solubility 
CP carrier payload 
dmean mean particle size of the compound 
ds degree of substitution 
D diffusion coefficient 
DSC differential scanning calorimetry 
D10% The diameter when 10 % of particles are under the indicated size 
D50% The diameter when 50 % of particles are under the indicated size 
D90% The diameter when 90 % of particles are under the indicated size 
ε  porosity of the matrix 
Et% percentage of expansion 
FTIR Fourier transform infrared 
γSD dispersive component of the surface free energy 
GI gastrointestinal 
h thickness of the diffusion layer 
Hbefore height of the cylinder of the tablet before the dissolution test 
Ht height of the cylinder of the tablet after the dissolution test and freeze 
drying 
HPLC high performance liquid chromatography 
IGC inverse gas chromatography 
IR infrared 
J flux 
k square root release constant 
ka erosion rate constant in the radial direction 
 
 
 
 
kb erosion rate constant in the vertical direction 
kdiffusion diffusional constant 
krelaxation relaxational constant 
M dissolved amount of drug at time point of t 
Mt amount of drug released at time t 
M∞ total amount of drug 
MD metronidazole 
n diffusional exponent 
N number of particles in the mixture 
PC paracetamol 
PCA principal component analysis 
PEG polyethylene glycol 
PLS partial least squares to latent structures 
Q2 prediction parameter 
QSAR quantitative structure-activity relationship 
R2 correlation coefficient 
S surface area of undissolved drug 
SA starch acetate 
SC salicylamide 
SEM scanning electron microscope 
τ tortuosity factor of the capillary system 
t time point 
TF theophylline 
USP United States Pharmacopoeia 
UV ultraviolet-visible 
V measured volume of the tablet  
V0 theoretical volume of the tablet 
X distance in the membrane 
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1 INTRODUCTION 
 
When a drug is taken by a patient, the resulting biological effects, for example 
lowering of blood pressure, are produced via the interaction of the drug with specific 
receptors at the drug’s site of action (Hillery 2001). Solid oral dosage forms, due to 
their robustness, ease of product handling and convenience, are most commonly used 
in order to introduce the drug into the systemic circulation (Rudnic and Kottke 1996, 
Venkatraman et al. 2000). However, if the patients’ condition needs continuous 
medical treatment, a solid oral dosage form displaying an immediate drug release 
property is inconvenient and may even cause unwanted side-effects. 
   The unnecessarily frequent administration and other undesired features, such as 
side-effects or local irritation, can be avoided by utilisation of preparations that 
release their contents slowly into the gastrointestinal tract. These preparations are 
called using the term controlled release, but they are known by other names including 
slow release, extended release, sustained release and prolonged release (Alderborn 
2007). However, all of the preparations given via the oral route should exhibit 
controlled release behaviour instead of random release and, therefore, within the 
context of this thesis, these slowly releasing preparations are designated with the term 
prolonged release. In addition to this, another clarification needs to be done in order to 
avoid possible confusion. Many handbooks refer to water non-dissolving polymers 
using the term hydrophobic, although they are not per se hydrophobic, i.e. repulsive 
to water. Therefore, within the context of this thesis the term hydrophobic, when used 
to describe excipients or matrix tablets, is used as a synonym for water non-
dissolving, unless otherwise stated. 
   There are many different ways to achieve preparations having prolonged drug 
release properties, but the most common types are tablets (Lee and Robinson 1978, 
Rudnic and Kottke 1996, Venkatraman et al. 2000, Hayashi et al. 2005, Alderborn 
2007). However, in particular the production of matrix tablets is not simple, since 
many different factors contribute to the final properties of the tablet preparation. The 
factors affecting the formation of the tablet are attributable to the physicochemical 
properties of the tablets’ components, such as particle morphology and deformation 
properties, and processing, such as the mixing of the powder and compaction. In 
addition, the drug release mechanism and functionality of the prolonged release 
14 
 
 
 
preparation has to be optimized. This is most often performed routinely using in vitro 
dissolution tests, which are defined in the Pharmacopoeias. 
   In this thesis, the focus is on prolonged release hydrophobic matrix tablets, 
especially on the process and formulation parameters affecting their drug release 
properties during the in vitro dissolution test. To be more precise, the aim of the study 
was to identify methods to control the structure and subsequent drug release 
properties of hydrophobic starch acetate, with a degree of substitution 2.7, matrix 
tablets, relate the structural properties with the drug release behaviour, and, finally, to 
evaluate the functionality of in vitro drug release test. Therefore, in order to provide a 
more comprehensive presentation of the topic, the background of the study considers 
the following themes: oral administration, general principles and examples of 
prolonged drug delivery, in vitro dissolution tests, and tablet preparation, which 
includes the topics such as powder mixing and compaction. In addition, in the 
experimental section there are brief descriptions of analysing techniques, such as 
microcomputed tomography, Fourier transform infrared mapping and multivariate 
data analysis, which are rather new and unfamiliar in the field of pharmaceutics. 
15 
 
 
 
2 BACKGROUND OF THE STUDY 
 
 
2.1 Oral drug delivery 
   Drug treatment via the oral route is the most common and most convenient way to 
administer medications. Due to its non-invasive nature, it can be regarded as cost 
efficient, highly acceptable to patients and thus compliance enhancing. For that 
reason, the majority of the existing drug preparations are administered via oral route 
(Steele 2001, Qiu and Zhang 2000). In addition, it is likely that interest in the 
preparations given by mouth, i.e. systemic effects following the administration of 
preparation, such as tablet or capsule, and their development, will continue in the 
future. 
   The oral route is composed of parts, which are, in the order of appearance, the 
mouth, the stomach, the small intestine and the large intestine. Each part has one or 
more specific functions and therefore their properties differ vastly from each other. 
Thus, there are differences in the structure of tissue, such as surface area and extent of 
motility, chemical environment, such as range of pH and amount of moisture content, 
and biological activity, such as extent and diversity of enzymatic activity and 
microbiologic flora (Rowland and Tozer 1995, Guyton and Hall 2000a, Guyton and 
Hall 2000b, Lee and Yang 2001). In addition to mentioned, there are always inter- 
and intra-patient variations present.  
   In order to enter the general systemic circulation and evoke systemic effect after 
being taken by the oral route, a drug must dissolve from the preparation and pass from 
the gastrointestinal lumen, through the gut wall and through the liver (Rowland and 
Tozer 1995). However, this may not be a simple issue, since the characteristic 
structure and function of each part of the oral route can generate a rather hostile 
environment for the preparation and drug compound. 
 
 
2.2 Prolonged oral drug delivery 
   The target of prolonged oral drug delivery is to produce preparations having 
increased therapeutic efficiency by reducing fluctuations in plasma concentrations, as 
well as increased patient compliance by reducing the administration to once or twice a 
day (Venkatraman et al. 2000).  
16 
 
 
 
   One should consider the possibility of prolonged drug delivery if one or more of the 
following drug compound properties exist (Rowland and Tozer 1995, Jantzen and 
Robinson 1996, Qiu and Zhang 2000): 
 
1. High water solubility 
2. High permeability 
3. Low effective dose 
4. Wide therapeutic window 
5. Poor physicochemical stability 
6. Low first pass metabolism 
7. Short half-life 
 
   Although prolonged oral drug delivery possesses significant benefits, they are not 
per se desirable solutions for drug delivery. According to Ballard (1978) there are 
some disadvantages associated with prolonged release attributable to various sources. 
The structure of prolonged release preparations is more delicate and can be more 
expensive than immediate release systems and therefore the unjustified utilization of 
such a preparation is a waste of resources. If drug compound has a specific absorption 
site, i.e. the upper part of small intestine, the prolonged drug release properties may 
not guarantee adequate absorption. Since drug loading of prolonged release 
preparation may be substantially high, the accidental or intentional collapse of the 
preparation can lead to acute poisoning. If the daily dose is high, i.e. from one to three 
grams, the physical size of the preparation may be too large to swallow. Finally, due 
to inter-individual variations in the function of GI tract an individual having a delayed 
gastrointestinal transit time may suffer from local irritation. 
 
 
2.3 Types of prolonged oral delivery systems 
   Prolonged oral drug delivery systems can be classified into either single-unit or 
multiple-unit systems and their principle of drug release can be divided roughly into 
the following groups (Lee and Robinson 1978, Jantzen and Robinson 1996, 
Venkatraman et al. 2000, Hayashi et al. 2005, Alderborn 2007): dissolution-
controlled, diffusion-controlled, ion exchange resins, osmotic controlled release and 
gastroretentive systems. 
17 
 
 
 
   In dissolution-controlled prolonged preparations, the rate of dissolution of the drug 
or some other tablet ingredient in the GI juices is the release-controlling step 
(Alderborn 2007). Thus, a sparingly water soluble drug can be thought to be per se a 
dissolution-controlled preparation. Generally, the dissolution-controlled approach can 
be used with compounds having moderate to great and pH dependent solubility 
(Streubel et al. 2000, Alderborn 2007). Dissolution-controlled prolonged release 
properties can be achieved by incorporating the drug compound in a slowly dissolving 
or eroding carrier or coating, i.e. the drug release results as a dissolution or erosion of 
the carrier or coating, or the drug can be in a non-dissolving carrier, i.e. the drug 
release results when the penetrating liquid reaches and dissolves the drug compound 
(Venkatraman et al. 2000, Abdul and Poddar 2004, Alderborn 2007, Cao et al. 2007). 
   In diffusion-controlled systems, the release limiting process is the transport by 
diffusion of the dissolved drug in pores filled with surrounding liquid or in a solid 
phase, i.e. polymer (Alderborn 2007). This can be achieved by utilisation of an 
insoluble coating or a insoluble or swelling carrier (Abdul and Poddar 2004, Strübing 
et al. 2007, Siepmann et al. 2008). In the first case, the drug has to dissolve into 
coating and in the latter, the compound has to diffuse through a liquid filled material, 
i.e. pores or gel layer. This approach is suitable with compounds having a variety of 
solubilities and can achieve a uniform drug release rate; however the collapse of the 
diffusion restricting step might cause undesirably high drug release rates. 
   Ion-exchange resins consist of a cross-linked insoluble polymer backbone carrying 
ionisable functional groups, to which the drug is attached in an ionic form 
(Venkatraman et al. 2000, Anand et al. 2001, Pongjanyakul 2007). These groups are 
able to exchange the attached drug compound with ions from the surrounding liquid 
and subsequently the drug is released by diffusion (Florence and Attwood 1998). Ion-
exchange resins provide uniform drug release and, in theory, their function in the GI 
tract is robust, since they are immune to enzymatic attack (Venkatraman et al. 2000, 
Anand et al. 2001). However, the pH and ionic strength varies between different parts 
of GI tract and there are always deviations between individuals. Therefore, the 
robustness of this system is questionable. 
   The function of osmotic controlled release preparation is based on the difference in 
osmotic pressure between two compartments which are separated using 
semipermeable membrane (Martin 1993a, Florence and Attwood 1998, Venkatraman 
et al. 2000, Verma et al. 2000, Verma et al. 2002). Basically, the osmotically active 
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core consisting of the drug compound or an excipient draws surrounding liquid into 
the preparation, creating a pressure which will force the drug compound to diffuse out 
from a specially designed orifice. The benefits of this system include achievement of 
uniform drug release, suitability for compounds having water solubility from 
moderate to extreme and a functionality regardless of the surrounding environment, 
i.e. changes in pH, ionic strength and microbiological activity (Verma et al. 2000, Lee 
and Yang 2001, Verma et al. 2002). However, due to their delicate structure, their 
functionality is sensitive to deviations in their manufacture and furthermore they may 
be considered to be expensive to mass produce (Verma et al. 2000). 
   The principle of gastroretentive systems is that the transit of the preparation from 
stomach to small intestine is delayed or prevented by altering the size or the density of 
the preparation (Moës 1993, Hou et al. 2003, Talukder and Fassihi 2004, Bardonnet et 
al. 2006). These systems enable prolonged release in the upper part of GI tract and are 
useful not only for prolongation of drug release, but also especially suitable for drug 
compounds that are effective locally in the stomach, have poor solubility at the higher 
pH of small intestine or are unstable in the colon (Reddy and Murthy 2002, Bardonnet 
et al. 2006). It is notable that gastroretentive systems are not suitable for compounds, 
which may cause gastric lesions or which are not stable in acidic conditions (Talukder 
and Fassihi 2004). Furthermore, the differences in transit properties, i.e. time and the 
size of the object, among individuals can result in unintentional loss of the preparation 
during gastric emptying and this can lead variations in drug release properties 
(Bardonnet et al. 2006). 
 
 
2.3.1 Matrix tablets 
   On the basis of the previous chapter, it can be concluded that the challenge for 
producing preparations with prolonged drug release properties can be met in a large 
variety of ways. However, the most common prolonged release system has been the 
matrix tablets because of their effectiveness, low cost and ease of manufacturing 
(Abdul and Poddar 2004). In matrix tablets, the drug compound is either dissolved 
molecularly or suspended physically as a particle mixture into the surrounding 
excipient (Martin 1993a, Hillery 2001, Alderborn 2007). In its simplest form the 
matrix tablet consists of a single-unit and can be referred to as monolithic. However, 
there are matrix tablets available with a multiple unit structure, i.e. they consist of two 
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or more parts, such as individual layers containing drug compound or excipient 
(Chidambaram et al. 1998, Qiu et al. 1998). In this thesis, the monolithic matrix 
tablets are the focus of interest and, therefore, the other types of matrix tablets are not 
discussed further in the following sections. 
   The easiest and, thus, most generally applied method to produce orally 
administerable prolonged release matrix tablets is the direct compression of a physical 
mixture consisting of drug compound, matrix forming polymer and, if needed, other 
excipients (Sánchez-Lafuente et al. 2002, Le Tien et al. 2003, Nabais et al. 2007, 
Abdelbary and Tadros 2008, Corti et al. 2008). Direct compression can provide not 
only economical but also technical benefits; stability and dissolution improvements 
for some drugs have been attributed to direct compression (Davies 2001). In cases 
where the existing powder lacks suitable properties prior to tableting, the powder can 
be processed. The typical processing methods are wet and dry granulation and 
extrusion, which are commonly done with powders, and melting, which is especially 
used with formulations containing waxes (Davies 2001, Tiwari et al. 2003, Kiortsis et 
al. 2005, Hayashi et al. 2005, Kuksal et al. 2006, Patel et al. 2006). However, direct 
compression of physical mixtures containing drug and excipient is convenient, and is 
the most widely used method to produce matrix tablets but the processing per se is 
complicated and thus the processes of granulation, extrusion and melting are not dealt 
within the context of this thesis. 
 
 
2.3.1.1 Hydrophobic excipients for matrix tablets 
   The excipients, which have no dissolving or swelling properties and are used in the 
formation of hydrophobic matrix tablets, are generally waxes and polymers. Waxes 
are high molecular weight excipients without liquid components composed of 
hydrocarbons containing straight, branched or cyclic alkanes (Walters and Brain 
2001). Waxes, such as carnauba wax, yellow wax, microcrystalline wax, and waxlike 
polymers, such as glycerides, can be used alone or with other excipients to produce 
prolonged release solid-dosage formulations (Yonezawa et al. 2002, Cao et al. 2007, 
Oladiran and Batchelor 2007, Rowe et al. 2009). When used as an additive, they can 
form complexes by combining with hydrophilic polymers resulting in the creation of 
in preparations having prolonged drug release properties (Hayashi et al. 2005, 
Abdelbary and Tadros 2008). 
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   Polymers for prolonged release hydrophobic matrix tablets can be either natural or 
chemically modified natural materials, e.g. starch, cellulose and chitin, and their 
derivatives, or synthetic products, e.g. acrylate derivatives (Le Tien et al. 2003, 
Siepmann et al. 2008, Rowe et al. 2009). The originally swelling or dissolving 
polymers can be transformed into more hydrophobic derivatives by changing the 
degree of polymerisation, adding cross-linkages or introducing hydrophobic groups 
into the polymer backbone (Te Wierik et al. 1993, Raatikainen et al. 2002, Le Tien et 
al. 2003, Grassi and Grassi 2005, Nabais et al. 2007, Ching et al. 2008). The range of 
hydrophobic polymers for prolonged matrices is wide, but the most commonly used 
are polyethylene, polypropylene, polyvinyl chloride and polyvinyl acetate (Florence 
and Attwood 1998, Venktraman et al. 2000, Grassi and Grassi 2005, Rowe et al. 
2009). 
 
 
2.3.1.2 Starch acetate 
   Starch consists of two polysaccharides based on α-glucose: linear amylase and 
highly branched amylopectin (Young 1984, Rowe et al. 2009). The properties of 
starch are affected by its botanical source, but they all share common features: they 
are hygroscopic, insoluble in cold water, swellable up to 5–10 % at 37ºC and soluble 
in hot water at temperatures above the gelatinization temperature. Starch is widely 
used as an excipient primarily in oral solid dosage formulation where it is utilized as a 
binder, diluent and disintegrant (Rowe et al. 2009). 
   Starch acetates are modified starches produced by mixing the native starch with 
acetic acid anhydride in the presence of a catalyst (Raatikainen et al. 2002, Pohja et al. 
2004). The modification converts starch into more a hydrophobic derivative by 
replacing original hydroxyl groups by acetyl groups (Fig. 1) and the hydrophobicity 
increases proportionally as the degree of substitution (ds) increases from 0 up to 3.0. 
Starch acetate possesses a number of beneficial properties compared to unmodified 
starch. Its flowing properties are suitable for direct compression, it exhibits both 
plastic deformation and fragmentation under pressure, it has excellent binding 
properties when ds is greater than 1.19 and, finally, it produces tablets with sustained 
drug release properties when ds is greater than 2.1 (Korhonen et al. 2000, Korhonen et 
al. 2002, Raatikainen et al. 2002, Pohja et al. 2004).  
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Figure 1. Starch acetate is produced by acetylating native starch monomer into fully 
acetylated (ds 3.0) starch acetate monomer.  
 
 
2.3.2 Drug release from hydrophobic matrix tablet 
   The solid drug has to dissolve and diffuse out from the preparation in order to 
become systemically available. Thus, the concept of drug release, i.e. mass transfer 
from a hydrophobic matrix can be proposed to be based on two different phenomena: 
dissolution of solid and diffusion. However, since the tablets are complex systems and 
the drug release is very complicated, a knowledge of dissolution rate and diffusion is 
not sufficient to describe the situation of drug release in a comprehensive manner. 
This thesis concentrates on two main mechanisms for depicting the method of drug 
release from hydrophobic matrix tablets: drug release by diffusion and by erosion. 
Thus, in the following chapters, in addition to mass transfer, these main drug release 
mechanisms and the most common mathematical equations describing these 
phenomena are discussed. 
 
 
2.3.2.1 Dissolution rate of solids 
   When a tablet or other solid drug form is introduced into a liquid, the drug begins to 
pass into solution from the intact solid. Noyes and Whitney (1897) have proposed an 
equation describing the rate at which a solid dissolves in a solvent 
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where M is the dissolved amount of drug at time point of t, D is the diffusion 
coefficient, S is the surface area of the dissolving solid, h is the thickness of the 
diffusion layer, Cs is the saturation solubility of the solid and C is the concentration of 
solute in bulk solution at time point of t. It has to be emphasized that the drug 
solubility alone is not a simple issue since it is dependent of the properties of drug 
molecule, such as polymorph forms, complexes and purity, and solvent properties, 
such as temperature, pH and consistency (Martin 1996b, Röst and Quist 2003). 
 
 
2.3.2.2 Diffusion 
   Diffusion is defined as a process of mass transfer of individual molecules of a 
substance, brought about by random molecular motion and associated with a 
concentration gradient (Martin 1996a). Diffusion has been described by the Fick first 
law as follows: 
 
dX
dCDJ       (2) 
 
where J is the flux, D is the diffusion coefficient of the drug in the membrane and 
dC/dX represents the rate of change in concentration C relative to distance X in the 
membrane. 
 
 
2.3.2.3 Drug release by diffusion 
   There are two main drug release mechanisms from hydrophobic matrices: diffusion 
and erosion and their importance depends on the formulation and structure of the 
preparation (Steendam et al. 2000, Hayashi et al. 2005, Cao et al. 2007). The main 
difference in these mechanisms is that when the drug release occurs by diffusion, the 
drug release restricting matrix remains intact. Many authors have described diffusion 
from tablet preparations composed of both waxes and as well as from hydrophobic 
polymers (Pather et al. 1998, Steendam et al. 2000, Steendam et al. 2001, Reza et al. 
2003). The schematic illustration of diffusion is presented in Figure 2 and the 
principles of the mechanism are as follows: when a tablet is immersed into a liquid 
environment, liquid starts to penetrate into the matrix through the pores. As the liquid 
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reaches the drug compound, it starts to dissolve and, finally, the dissolved drug 
molecule diffuses out through the liquid filled pores of the matrix. 
 
      Trapped
   drug particles
 Polymer
   matrix
   Drug
 particles
 Liquid
 boundary  Channels formed
 by leaching of drug
 Liquid  Pores
t=0 t=t’
 
 
Figure 2. The schematic illustration of diffusion in a hydrophobic matrix tablet 
(modified from Steendam et al. 2000). 
 
 
   Higuchi (1963) has proposed that a drug release from hydrophobic matrices can be 
described by the equation 
 
tCCADM sst )2(      (3) 
 
where Mt is the amount of drug released after time t per unit exposed area, D is the 
diffusitivity of the drug in the permeating fluid, τ is the tortuosity factor of the 
capillary system, A is the total amount of drug present in the matrix per unit volume, 
Cs is the solubility of the drug in the permeating fluid and ε is the porosity of the 
matrix. When the drug release mechanism is diffusion-based the diffusion path grows 
as a function of time, which will affect the drug release rate i.e. it will decline as more 
and more drug is release. Therefore, the drug release rate occurs by square root 
kinetics, which is generally expressed as follows 
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where Mt is the amount of drug released at time t and M∞ is the total drug amount and 
k is a constant.  
   Although the Higuchi model has a high degree of approximation, it is widely used 
due to its simplicity (Siepmann and Peppas 2001, Grassi and Grassi 2005). However, 
there are many other empirical and semi-empirical release models describing drug 
release phenomena. In addition to the Higuchi model, widely used models with the 
best abilities to describe the phenomena are the zero-order model, the Weibull model 
and the Korsmeyer-Peppas model (Costa and Sousa Lobo 2001). However, the 
creation of empirical and semi-empirical models describing drug release may be time-
consuming. Therefore, numerical methods, such as the finite difference and the finite 
element methods, have been introduced (Zhou and Wu 1997, Wu and Zhou 1998, 
Frenning et al. 2005). 
 
 
2.3.2.4 Drug release by erosion 
   When drug release occurs by erosion, the preparation will gradually erode which 
will ultimately expose the solid drug for dissolution and diffusion. Erosion can result 
as a change in the matrix forming polymer backbone or dissolution of one or several 
components of the preparation. Changes in polymer backbone can be due to 
degradation, i.e. the polymer chains are cleaved to form oligomers and monomers 
chemically via hydrolysis or enzyme-catalysed hydrolysis, or erosion, i.e. the loss of 
material due to monomers and oligomers being released from the polymer (Göpferich 
1996, Siepmann and Göpferich 2001, Grassi and Grassi 2005). Erosion of the 
preparation may result from either bulk (homogenous) or surface (heterogenous) 
erosion as shown in Figure 3.  
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Figure 3. Schematic illustration of (a) bulk and (b) surface erosion (modified from 
Göpferich 1996, Siepmann and Göpferich 2001). 
 
 
   In bulk eroding preparations, polymers degrade and erode throughout the matrix 
since water diffusion into the matrix is substantially faster than the degradation of the 
polymer and thus the size of the preparation remains constant (Göpferich 1996, Grassi 
and Grassi 2005). In surface eroding preparations, the water penetration is slower than 
the polymer degradation which means that the preparations become smaller but keep 
their original geometric shape. (Siepmann and Göpferich 2001, Grassi and Grassi 
2005). Both types of the erosion of the preparation have been reported to occur with 
hydrophobic polymer based matrices (Göpferich 1996, Te Wierik et al. 1997a, 
Tuovinen et al. 2002). 
   However, the reason for erosion of the hydrophobic polymer based tablets is not 
likely to be the degradation or erosion of the matrix forming polymer. Due to 
hydrophobic nature of the polymer, the water uptake and consequent hydrolysis of 
water-labile structures may be restricted (Grassi and Grassi 2005). A more probable 
reason for erosion is a reduction of the cohesiveness of the tablet due to dissolution of 
the drug compound or other excipient and subsequent cleavage of the binding forces 
between particles (Pather et al. 1998, Barra et al. 2000). In other words, prolonged 
drug release hydrophobic matrix tablets having erosion as release mechanism exhibit 
more often surface erosion than bulk erosion. 
   Katzhendler et al. (1997) have derived the following equation for drug release from 
erodible tablets: 
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where Mt is the amount of drug released at time t and M∞ is the total drug amount, C0 
is total amount of drug in a unit volume of the matrix, a0 and b0 are the initial radial 
and vertical dimensions of the tablet, ka and kb represent the erosion rate constant in 
the radial and vertical directions. Erosion can theoretically produce zero-order drug 
release kinetics, i.e. the drug release rate is constant as a function of time, which can 
be generally expressed using the following equation 
 
kt
M
M t       (6) 
 
where Mt is the amount of drug released at time t and M∞ is the total drug amount and 
k is a constant. However, the true zero-order drug release kinetics can be achieved 
only if the following conditions are fulfilled: the drug diffusion is slow within the 
polymer matrix compared to the rate of erosion, surface erosion occurs and the 
surface area does not change with time (Jantzen and Robinson 1996). Since there are 
strict limitations for zero-order release and there are many factors related to the drug 
compound and polymer, which can affect these properties, the kinetics of eroding 
tablets may be difficult to control and, furthermore, it seems that eroding tablets often 
exhibit apparent zero-order kinetics. 
 
 
2.3.2.5 Drug release by erosion and diffusion 
   The drug release mechanism can be often classified into diffusion or erosion since 
the dominant mechanism will overshadow other processes. However, in practice the 
mechanism can change as a function of time, be parallel and even promote each other 
(Jantzen and Robinson 1996, Göpferich 1997, Te Wierik et al. 1997b, Zuleger and 
Lippold 2001). Thus, modeling and controlling of the drug release mechanism and 
rate using approaches based strictly on either diffusion or erosion theories is not 
always satisfactory. 
   In attempts to describe the release behaviour of tablets showing a combination of 
Fickian diffusion and Case II relaxation, i.e. the influence of polymer relaxation on 
molecules’ movement in the matrix, Ritger and Peppas (1987) and Peppas and Sahlin 
(1989) derived an equation depicting diffusion and relaxation mechanisms as the 
limiting factors of controlled drug release: 
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where Mt is the amount of drug released at time t, M∞ is the total drug amount, kdiffusion 
is the diffusional constant, krelaxation relaxational constant and, thus, the first term on 
the right-hand side of the expression represents the Fickian contribution and the 
second term the Case II relaxation contribution to the fractional drug release. The 
purely Fickian diffusion exponent n and the relaxation exponent, which is two times 
the factor n, depend on the aspect ratio between tablet diameter and height. These 
exponents for cylindrical tablets derived from studies by Ritger and Peppas (1987) 
have been reported to have values of 0.45 and 0.89 for the diffusional and relaxational 
exponent, respectively. 
 
 
2.4 In vitro dissolution tests 
   The drug release mechanism and rate of the preparation have to be determined in 
order to ensure both consistency and safety of the product. European (2007) and 
United States (2009) Pharmacopoeias contain definitions of in vitro dissolution tests, 
which provide information on release mechanism and kinetics. The principle of the in 
vitro dissolution test is to imitate the general conditions in the human body, which is 
commonly achieved by utilization of an appropriate medium, hydrodynamic 
conditions and adjusting the temperature to 37 ºC. There are four different in vitro 
dissolution tests for solid dosage forms which, in the order given by the 
Pharmacopoeias, are basket apparatus, paddle apparatus, reciprocating cylinder and 
flow-through cell. All these apparatuses can be used to investigate the functionality of 
prolonged release preparations, but the first two are the most widely used as 
formulation development tools and quality control tests (Qureshi and McGilveray 
1999, Azarmi et al. 2007, Gray et al. 2009). Thus, the focus of interest in this thesis 
will be on the basket and paddle methods. 
   In vitro dissolution tests are standardised by the Pharmacopoeias in order to 
improve their reproducibility: the materials and dimensions of vessels, baskets and 
paddles, location of sampling and procedure of de-aeration are strictly defined. 
Nonetheless, it has been reported that dissolution tests performed with equipment in 
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accordance with the Pharmacopoeias can produce data with unacceptable variations 
(Cox et al. 1982, Qureshi and McGilveray 1999, Tanaka et al. 2005, Deng et al. 2008, 
Bai and Armenante 2009). This is a problem and, thus, the relevance and reliability of 
the dissolution tests with prolonged preparations is recognized as being problematic 
(Qureshi and McGilveray 1999). Despite the evidence of the variance among results, 
there have been extensive studies which have concluded that in vitro tests yield 
reproducible data and they can even simulate in vivo situations under certain 
conditions (Siewert et al. 2002, Scholz et al. 2003, Crail et al. 2004, Azarmi et al. 
2007). 
   Although some parameters are well defined, the Pharmacopoeias leave some 
freedom for the choice of the apparatus, time points for sampling, the amount, 
composition and temperature of the dissolution medium, and stirring speed, since 
their optimal properties are considered to be dependent on the physicochemical 
characteristics of the dosage form. However, all of these variables have an impact on 
the results. The nature and the effect of these variables are presented in more detail in 
Table1. Thus, the optional parameters of in vitro test need to be chosen carefully. 
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Table 1. The nature and effect of method variables in drug release behaviour of 
prolonged release preparation during in vitro dissolution test. 
Method variable Nature of the effect of the method variable Reference 
Basket apparatus  Tablet is immersed into a basket and medium can 
flow rather freely and homogenously over all 
surfaces of the tablet. There are high velocity 
regions at the sides of the basket. The basket 
method produces data with less extensive 
variability than the paddle method, but 
disintegrating dosage forms may be ejected 
through the basket and pass into a low velocity 
zone. 
 
D’Arcy et al. 2006, Deng et 
al. 2008, Morihara et al. 
2002, Tandt et al. 1994 
Paddle apparatus Tablet is immersed at the bottom of the vessel and 
medium can flow at the top planar surface and at 
the edges of the tablet, but not at the lower 
surface. Paddle apparatus has highly non-uniform 
hydrodynamic pattern: high velocity regions at 
the bottom edge of vessel and dead zone directly 
under the paddle, responsible for a coning effect, 
i.e. formation of loosely aggregated particles. 
Paddle apparatus produces higher release rates 
than basket apparatus, but is very sensitive to the 
location of the tablet during the test. 
 
Bai et al. 2007, Bai et al. 
2008, Bai and Armenante 
2009, Baxter et al. 2005, 
D’Arcy et al. 2005, Gray et 
al. 2009, Healy et al. 2002, 
Morihara et al. 2002, Qureshi 
and Shabnam 2001, Wu et al. 
2004 
Materials Inert materials, such as glass or plastic, should be 
used. However, some compounds may undergo 
interactions with these materials. 
 
Cox et al. 1982 
Sampling time The time points of sampling should produce 
adequate conditions for continuous monitoring. 
Sampling time points at the beginning of the test 
(< 1 minute) may be too early, due to unbalanced 
conditions inside the dissolution vessel and lead 
to unwanted variation. 
 
McCarthy et al. 2004, 
Siewert et al. 2002 
Medium Amount of medium should be sufficient enough 
in order to obtain sink conditions, i.e. the 
concentration of solute is considerably less than 
the maximum solubility. 900 ml is typically 
adequate, but smaller amounts, such as 500 ml, 
may be used in order to achieve similar results. 
However, a reduction of medium volume may 
result in deviations in hydrodynamic pattern and 
lower drug release rates, especially if 
geometrically smaller vessels are used. 
 
Typically the medium is a buffer solution with a 
pH of 6.8, imitating the conditions of the 
intestine. Moreover, the Pharmacopoeias state 
that one can use buffers containing different pHs, 
surfactants and enzymatic activities in order to 
better mimic the conditions present in the GI 
tract. These alterations are connected with degree 
of ionization of the compound, degradation and 
erosion process of the preparation, and ultimately 
may affect the drug release rate. Lately, more 
physiologically adapted and biorelevant 
dissolution media have been developed in order to 
improve the in vitro – in vivo correlation. 
Azarmi et al. 2007, Crail et 
al. 2004, Gray et al. 2009, 
Lozano et al. 1994, Martin 
1993a, Nikolić et al. 1992, 
Röst and Quist 2003, Scholz 
et al. 2003 
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Table 1. The nature and effect of method variables in drug release behaviour of 
prolonged release preparation during in vitro dissolution test (cont.). 
Method variable Nature of the effect of the method variable References 
Medium Increase in temperature increases the maximum 
solubility and diffusion coefficient and, thus, 
dissolution rate. However, the impact of this 
feature has been reported to be small or even 
insignificant. 
 
 
Stirring The purpose of stirring is to remove the drug-
saturated layer from around the preparation and to 
replace it with fresh medium. The same stirring 
speed produces almost similar hydrodynamic 
velocities in basket and paddle apparatuses. 
Greater stirring produces higher drug release 
rates, but does not achieve greater homogeneity in 
the hydrodynamic pattern. Inadequate stirring can 
not only cause reduced drug release rates, but also 
a non-uniform drug accumulation inside the 
matrix tablet. 
Baxter et al. 2005, Baxter et 
al. 2006, Gray et al. 2009, 
D’Arcy et al. 2006, Nikolić 
et al. 1992, Scholz et al. 
2003, Wu et al. 2004, Zhou 
and Wu 1997 
 
 
   Despite the fact that the existing in vitro dissolution tests are considered to produce 
adequate data, several groups have made a number of attempts to improve the 
robustness and reproducibility of these tests. The problems associated with high 
variability in the results can be traced to the variable flow-dynamics and poor mixing 
and stirring (Qureshi and Shabnam 2001). Thus, most often the improvement attempts 
consist of geometrical alterations of one or several parts, such as the impeller and the 
vessel, which are responsible on the hydrodynamic conditions and which on the 
dissolution rate of the preparation is strongly dependent (McCarthy et al. 2004, Wu et 
al. 2004, D’Arcy et al. 2005, Bai et al. 2007). Therefore, the role of the impeller is 
crucial and it has been shown that the shape, diameter and area of the paddle and even 
small changes in the location of the regular paddle can be used to produce 
hydrodynamically favorable conditions for drug dissolution (Röst and Quist 2003, Wu 
et al. 2004, Baxter et al. 2006, Bai and Armenante 2009). In addition, the design of a 
paddle was taken a step further when a specially curveshaped spindle was introduced 
(Qureshi and Shabnam 2001, Qureshi 2004). This novel paddle enabled more 
biorelevant characterization for prolonged release preparations by providing more 
efficient mixing and preventing the formation of loosely aggregated particles under 
the impeller resulting from the disintegration of the preparation, which is known as 
the coning effect, a common problem encountered with the paddle method (Gao et al. 
2009). The modifications of basket method have not been so intensively investigated 
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(Gray et al. 2009), but Crist and Spisak (2005) reported that a basket attachment with 
smooth surface and mesh containing fewer openings and larger wire could result in 
lower release rates. 
   The vessel is the other feature which strongly affects the hydrodynamic pattern. 
Studies have shown that the 200 ml vessel produces lower drug release rates than the 
regular vessel and longitudinal type sinkers lead to higher drug release rates and less 
variable results than lateral sinkers (Soltero et al. 1989, Crail et al. 2004). However, 
with an adequate stirring setup the 200 ml vessel may produce comparable results to 
that achieved by the 1000 ml vessel (Crail et al. 2004). The coning effect has been 
also prevented by geometrical alterations of the vessel. This has been achieved by 
utilization of an inverted cone molded into bottom, known as the commercially 
available PEAK vessel, or a metal strip at the bottom of a regular vessel (Qureshi and 
Shabnam 2001, Mirza et al. 2005, Baxter et al. 2006, Gray et al. 2009). 
 
 
2.5 Structural properties of matrix affecting drug release 
   On basis of previous chapter, it can be concluded that the drug release rate can be 
affected by the choice of the in vitro dissolution test parameters. However, the drug 
release from hydrophobic matrix tablets is mostly dependent on structural properties 
of the preparation. These properties consist of the composition of the surface of the 
tablet, porosity, tortuosity of the capillary network, drug loading, percolating network, 
tablet hardness and geometry. An overview of the effect of each property, and the 
basic methods to control them, has been gathered in Table 2. Some properties, e.g. 
drug loading, are rather easy to control by simply increasing the amount of drug in the 
original powder formulation, but the other properties, such as percolating network, 
porosity and tablet hardness, are dependent on many factors, i.e. particulate 
interactions, the mechanical properties of the material and compression, and thus their 
control is complicated. 
 
 
 
 
 
32 
T
ab
le
 2
. T
he
 p
ro
pe
rti
es
 o
f h
yd
ro
ph
ob
ic
 m
at
rix
 ta
bl
et
, a
nd
 th
ei
r g
en
er
al
 c
on
tro
lli
ng
 m
et
ho
ds
, a
ff
ec
tin
g 
th
e 
dr
ug
 re
le
as
e 
ra
te
 a
nd
 m
ec
ha
ni
sm
. 
Pr
op
er
ty
 
Ef
fe
ct
 o
n 
dr
ug
 re
le
as
e 
M
et
ho
d 
of
 c
on
tro
l 
R
ef
er
en
ce
 
Po
ro
si
ty
 
In
cr
ea
se
 o
f 
po
ro
si
ty
 a
nd
 d
ec
re
as
e 
of
 t
or
tu
os
ity
, 
i.e
. 
ch
an
ge
s 
in
 re
la
tiv
e 
de
ns
ity
, e
nh
an
ce
s 
liq
ui
d 
pe
ne
tra
tio
n 
an
d 
in
cr
ea
se
s 
su
bs
eq
ue
nt
 t
ab
le
t 
di
si
nt
eg
ra
tio
n 
an
d/
or
 
di
ff
us
io
n 
ou
t f
ro
m
 th
e 
m
at
rix
.  
 
Po
ro
si
ty
 
ca
n 
be
 
co
nt
ro
lle
d 
by
 
th
e 
co
m
pa
ct
io
n 
pr
oc
es
s, 
bu
t 
th
e 
m
ec
ha
ni
ca
l 
pr
op
er
tie
s 
of
 
m
at
er
ia
ls
 
an
d 
co
m
po
si
tio
n 
m
ix
tu
re
 a
ls
o 
m
ak
e 
a 
co
nt
rib
ut
io
n.
 
 
Te
 W
ie
rik
 e
t a
l. 
19
97
b,
 T
e 
W
ie
rik
 e
t a
l. 
19
97
a,
 B
ar
ra
 e
t 
al
. 
20
00
, 
Si
nk
a 
et
 a
l. 
20
09
, S
te
en
da
m
 e
t a
l. 
20
00
 
D
ru
g 
lo
ad
in
g 
In
cr
ea
se
 i
n 
dr
ug
 l
oa
di
ng
 c
an
 r
es
ul
t 
in
 h
ig
he
r 
dr
ug
 
re
le
as
e 
ra
te
 a
nd
 c
ha
ng
e 
th
e 
m
ec
ha
ni
sm
. C
or
e 
ce
nt
er
ed
 
dr
ug
 lo
ad
in
g 
ca
n 
pr
od
uc
e 
ze
ro
-o
rd
er
 k
in
et
ic
s. 
 
D
eg
re
e 
of
 
dr
ug
 
lo
ad
in
g 
ca
n 
be
 
af
fe
ct
ed
 
si
m
pl
y 
by
 
in
cr
ea
si
ng
 
or
 
de
cr
ea
si
ng
 
th
e 
am
ou
nt
 
of
 
dr
ug
 
in
 
th
e 
or
ig
in
al
 
po
w
de
r 
fo
rm
ul
at
io
n.
 
 
Te
 W
ie
rik
 e
t 
al
. 
19
97
a,
 P
at
he
r 
et
 a
l. 
19
98
, 
W
u 
an
d 
Zh
ou
 1
99
8,
 N
ea
u 
et
 a
l. 
19
99
, G
ra
ss
i a
nd
 G
ra
ss
i 2
00
5  
Pe
rc
ol
at
in
g 
ne
tw
or
k 
C
on
si
st
in
g 
of
 a
 v
er
y 
so
lu
bl
e 
co
m
po
un
d,
 i
.e
. d
ru
g,
 t
he
 
dr
ug
 re
le
as
e 
ra
te
 m
ay
 in
cr
ea
se
 a
nd
 th
e 
m
ec
ha
ni
sm
 m
ay
 
be
 e
ro
si
on
, w
he
re
as
 if
 it
 is
 a
 h
yd
ro
ph
ob
ic
 p
ol
ym
er
 th
is
 
w
ill
 r
es
tri
ct
 d
ru
g 
re
le
as
e 
ra
te
; 
it 
pr
od
uc
es
 r
el
ea
se
 b
y 
di
ff
us
io
n .
  
 
Th
e 
co
ns
is
te
nc
y 
of
 t
he
 p
er
co
la
tin
g 
ne
tw
or
k 
an
d  
th
e 
su
bs
eq
ue
nt
 d
ru
g 
re
le
as
e 
m
ec
ha
ni
sm
 
ca
n 
be
 a
ff
ec
te
d 
by
 a
lte
rin
g 
th
e 
pa
rti
cl
e 
si
ze
 
fr
ac
tio
ns
 
of
 
dr
ug
 
co
m
po
un
d 
or
 
m
at
rix
 
fo
rm
in
g 
ag
en
t.  
 
B
ar
ra
 e
t 
al
. 
20
00
, 
G
ra
ss
i 
an
d 
G
ra
ss
i 
20
05
, R
ös
t a
nd
 Q
ui
st
 2
00
3,
 T
e 
W
ie
rik
 e
t 
al
. 1
99
7b
 
Su
rf
ac
e 
pr
op
er
tie
s  
H
yd
ro
ph
ob
ic
, i
.e
. r
ep
ul
si
ve
 to
 w
at
er
, s
ur
fa
ce
 h
as
 a
 lo
w
 
w
et
ta
bi
lit
y 
an
d 
th
is
 w
ill
 h
in
de
r 
w
at
er
 p
en
et
ra
tio
n 
in
to
 
ta
bl
et
, 
di
m
in
is
hi
ng
 t
he
 d
ru
g 
re
le
as
e 
ra
te
. 
A
 s
ur
fa
ce
 
co
nt
ai
ni
ng
 a
 l
ar
ge
 a
m
ou
nt
 o
f 
dr
ug
 m
ay
 i
nc
re
as
e 
dr
ug
 
re
le
as
e 
ra
te
 d
ue
 to
 th
e 
bu
rs
t e
ff
ec
t. 
 
Th
e 
su
rf
ac
e 
pr
op
er
tie
s 
ar
e 
str
on
gl
y 
lin
ke
d 
w
ith
 t
he
 s
tru
ct
ur
e 
of
 t
he
 t
ab
le
t, 
su
ch
 a
s 
th
e 
co
ns
is
te
nc
y 
of
 p
er
co
la
tin
g 
ne
tw
or
k,
 b
ut
 t
he
 
ut
ili
sa
tio
n 
of
 
ex
ci
pi
en
ts
, 
su
ch
 
as
 
hy
dr
op
ho
bi
c 
lu
br
ic
an
ts
, 
ca
n 
ha
ve
 
cr
uc
ia
l 
im
pa
ct
 o
n 
th
is
 p
ro
pe
rty
.  
 
D
ür
ig
 a
nd
 F
as
si
hi
 1
99
7,
 R
iip
pi
 e
t 
al
. 
19
98
, 
B
ar
ra
 
et
 
al
. 
20
00
, 
H
ua
ng
 
an
d 
B
ra
ze
r 2
00
1  
Ta
bl
et
 h
ar
dn
es
s 
Ta
bl
et
s 
w
ith
 
lo
w
 
te
ns
ile
 
st
re
ng
th
 
ha
ve
 
a 
fa
st
er
 
di
ss
ol
ut
io
n 
ra
te
, w
hi
ch
 m
ay
 b
e 
du
e 
to
 in
cr
ea
se
d 
er
os
io
n 
or
 e
nh
an
ce
d 
liq
ui
d 
pe
ne
tra
tio
n,
 s
in
ce
 t
he
 d
ec
re
as
e 
of
 
po
ro
si
ty
 
is
 
pr
op
or
tio
na
l 
to
 
th
e 
in
cr
ea
se
 
of
 
te
ns
ile
 
st
re
ng
th
.  
 
Ta
bl
et
 h
ar
dn
es
s i
s b
as
ic
al
ly
 c
on
tro
lle
d 
by
 th
e 
co
m
pa
ct
io
n 
pr
oc
es
s. 
H
ow
ev
er
, t
he
 s
itu
at
io
n 
is
 n
ot
 s
o 
si
m
pl
e,
 b
ec
au
se
 t
he
 p
ro
pe
rti
es
 o
f 
th
e 
co
m
pr
es
se
d 
m
at
er
ia
l a
nd
 e
xc
ip
ie
nt
s, 
su
ch
 
as
 lu
br
ic
an
ts
, h
av
e 
si
gn
ifi
ca
nt
 im
po
rta
nc
e.
  
 
R
ud
ni
k 
an
d 
K
ot
tk
e 
19
96
, 
Pa
th
er
 e
t 
al
. 
19
98
, 
St
ee
nd
am
 e
t 
al
. 
20
00
, 
Ty
e 
et
 a
l. 
20
05
 
Ta
bl
et
 g
eo
m
et
ry
 
In
cr
ea
se
 o
f t
he
 ra
tio
 o
f s
ur
fa
ce
 a
re
a 
fo
r d
ru
g 
to
 d
iff
us
e 
in
cr
ea
se
s 
th
e 
dr
ug
 
re
le
as
e.
 
G
eo
m
et
ric
al
ly
 
di
ffe
re
nt
 
ta
bl
et
s 
m
ay
 e
xh
ib
it 
va
ria
tio
ns
 i
n 
de
ns
ity
 a
nd
 p
or
e 
st
ru
ct
ur
e,
 w
hi
ch
 m
ay
 a
lte
r t
he
 d
ru
g 
re
le
as
e 
pr
op
er
tie
s.
 
Th
e 
ge
om
et
ry
 o
f 
th
e 
ta
bl
et
 p
re
pa
ra
tio
n 
ca
n 
be
 a
ffe
ct
ed
 s
im
pl
y 
by
 u
si
ng
 p
un
ch
es
 a
nd
 
di
es
 w
ith
 d
iff
er
en
t g
eo
m
et
rie
s.
 
K
im
 1
99
5,
 T
e 
W
ie
rik
 e
t a
l. 
19
97
a,
 Z
ho
u 
an
d 
W
u 
19
97
, S
ie
pm
an
n 
et
 a
l. 
20
00
, W
u 
et
 a
l. 
20
04
, 
Zu
le
ge
r 
an
d 
Li
pp
ol
d 
20
01
, 
D
je
m
ai
 e
t a
l. 
20
06
, S
in
ka
 e
t a
l. 
20
06
 
33 
 
 
 
2.6 Process and formulation properties affecting the formation of a matrix tablet 
   If one can control the factors determining the formation of the matrix tablet this will 
enable the achievement of desired drug release mechanism and rate, i.e. they are 
dependent on the properties of the tablet. The factors affecting the formation of the 
tablet are related to the powder, i.e. the interparticulate forces formed between the 
particles during the mixing responsible of the powder organization, and tableting, i.e. 
the forces and compaction speeds utilized for particle arrangement and volume 
reduction leading to formation of the tablet. For this reason, the following chapters 
will deal with parameters affecting the organisation of the powder blend and the 
compaction process. 
 
 
2.6.1 Organisation of the powder 
   Formulations for pharmaceutical preparations seldom consist of one ingredient only, 
especially when one tries to achieve prolonged release properties, other excipients are 
needed. If the preparation contains more than one component, mixing will need to be 
done prior to tableting. A theory of mixing and types of mixes has been well defined 
by several authors (Staniforth 1987, Davies 2001, Venables and Wells 2001, 
Twitchell 2007). Mixing can be defined as a unit operation that is intended to treat 
two or more components, initially in an unmixed or partially mixed state, so that each 
unit of the components lies as nearly as possible in contact with a unit of each of the 
other component. This ideal situation can be regarded as perfect mix. However, a 
random mix, which can be defined as a mix where the probability of selecting a 
particular type of particle is the same at all positions in the mix, is much more 
probable in practice. Furthermore, when one considers an ordered mix, the particles 
are not independent of each other and a degree of order is detected in the mix. An 
ordered mix is often due to adhesion of small particles on the surfaces of large 
particles and can produce greater homogeneity than a random mix. 
   The structure of the tablet is clearly dependent on the organization of the powder 
blend, which is the consequence of the interactions of its components (Nyström and 
Karehill 1996, Barra et al. 1999). Thus, it is crucial that one can control the mixing 
process and the particulate interactions responsible for the organisation. 
Interparticulate attractions can be divided into cohesion and adhesion: the first is the 
attraction between particles of the same material and the latter between different 
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materials (Führer 1996, Zeng et al. 2001a). Furthermore, the particulate interactions 
within a powder is a summation value of a number of concurrently acting forces or 
mechanisms, which are van der Waals, electrostatic, capillary forces and mechanical 
interlocking (Podczeck et al. 1997, Zeng et al. 2001a). Van der Waals forces are the 
major forces between uncharged solid particles; they are of an electrostatic nature, but 
are involved in interactions only over limited range (Führer 1996, Zeng et al. 2001a). 
Electrostatic charging, in most cases triboelectrostatic charging, is very common in 
pharmaceutical systems and is responsible for interactions over long distances by 
electrification: when two surfaces make contact, the transfer of electrons can occur 
resulting in surfaces with opposite charges after their separation (Führer 1996, 
Rowley 2001). Capillary forces occur when condensed moisture create an interaction 
by evoking liquid bridge formation between particles (Padmadisastra et al. 1994). 
Finally, mechanical interlocking occurs where adhesion is provided by interparticulate 
hooking of rough and irregular particles (Alderborn 2007). 
   The relative contribution of each individual force and mechanism to the overall 
interparticulate force is a function of the physicochemical and morphological 
properties of the interacting particles and the mixing process conditions, such as 
particle size, particle density, particle rigidity, particle shape, crystal form, surface 
area, surface energy, moisture content and relative humidity, and electrostatic 
properties (Führer 1996, Zeng et al. 2001b). An overview of the particle properties 
and process conditions affecting the organisation of the powder blend during mixing 
is presented in Table 3. Table 3 reveals that the organisation of the powder is a 
complicated process, since there are many simultaneous forces and mechanisms 
participating, many of them with multiple functions. This can be clarified with a short 
example: an increase in the moisture content decreases the triboelectrification by 
surface contamination, which will result in a decline of the adhesion (Eilbeck et al. 
2000, Rowley 2001). However, the increase in relative humidity will promote the 
liquid bridging and, as a consequence, increase the adhesive forces (Padmadisastra et 
al. 1994, Shimada et al. 2003, Murtomaa et al. 2004). Thus, the role of moisture is 
ambivalent. 
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Table 3. The properties of particles affecting the organization of the powder during 
the mixing. 
Property Effect Reference 
Particle size 
 
Small particles tend to fall into the void spaces 
between larger particles and, therefore, a nearly or 
completely identical particle size distribution 
prevents segregation during mixing if no other 
adhesion promoting factors are present. If the 
particle size difference is adequate, the small 
particles tend to adhere onto the surface of the 
larger ones producing an ordered mix. Small 
particles have a great surface area, i.e. area taking 
part in the interparticulate attraction, and thus, 
due to lower gravitational forces, they are more 
easily exposed to electrostatic interactions. 
 
Barra et al. 1998, Führer 
1996, Mäki et al. 2007, 
Nikolakakis et al. 2002, 
Nyström and Karehill 
1996, Patel et al. 2006, 
Rudnic and Kottke 1996, 
Twitchell 2007, Venables 
and Wells 2001 
Particle density 
 
The more dense particles tend to move 
downwards due to gravitational force. This 
phenomenon occurs even if the particles are of the 
same size. 
 
Staniforth 1981, Twitchell 
2007, Venables and Wells 
2001, Wadke and Jacobson 
1980 
Particle rigidity Rigid particles tend to have a lower adhesive 
force than deformable particles due to their 
smaller contact surface area. 
 
Feng 2001, Shimada et al. 
2003, Zeng et al. 2001b 
Particle shape 
 
Spherical particles are more easily mixed than 
irregular ones, which have a smaller contact 
surface area. However, the segregation of the 
irregular and rough particles may be prevented 
due to increased changes for mechanical 
interlocking. Furthermore, rough particles have 
extremely high values of electrostatic charge at 
the sharp corners and edges; whereas spherical 
particles have homogenously distributed values 
and therefore less active adhesion sites. Finally, 
the surface energy is dependent of the shape of 
particle. 
 
Führer 1996, Grimsey et al. 
2002, Nyström and 
Karehill 1996, Staniforth 
1987, Swaminathan and 
Kildsig 2000, Twitchell 
2007, Venables and Wells 
2001, Wong and Pilpel 
1990 
Crystal form 
 
A change in the crystal form may influence the 
adhesion affinity between particles. This takes 
place because the amorphous form and different 
crystal forms can exhibit different 
physicochemical properties, such as morphology, 
surface energy, hygroscopicity and density. 
 
Grimsey et al. 2002, 
Harjunen et al. 2002 
Murtomaa et al. 2004, Song 
and de Villiers 2004, Zeng 
et al. 2000, Zeng et al. 
2001b 
Surface area 
 
Greater contact surface area decreases segregation 
by increasing cohesive effects. In addition, this 
increases the potential for particulate interactions 
which arise from the properties of the surface, 
such as surface energy, moisture uptake and 
electrical properties. 
 
Feng 2001, Twitchell 2007, 
Venables and Wells 2001 
Surface energy 
 
Particles with a great surface energy have a high 
tendency to interact with other compounds, such 
as water and other particles. In the dry state, the 
interaction is due to van der Waals forces i.e. the 
interaction is likely to occur when the difference 
in surface energy of the particles is great. Surface 
energy is sensitive to contamination. 
Barra et al. 1999, Grimsey 
et al. 2002, Nikolakakis et 
al. 2002, Podczek et al. 
1997, Zeng et al. 2001a 
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Table 3. The properties of particles affecting the organization of the powder during 
the mixing (cont.). 
 
 
 
2.6.2 Compaction 
   Tablets are prepared by forcing particles into close proximity to each other by 
powder compaction, which transforms the particles into a porous, coherent compact 
form with a defined shape (Nyström and Karehill 1996, Alderborn 2007). The 
compression of the powder and the consequent tablet formation may involve the 
following processes: particle rearrangement, elastic deformation of particles, plastic 
deformation or fragmentation of particles and finally formation of interparticulate 
bonds (Nyström and Karehill 1996, Rudnic and Kottke 1996, Davies 2001). Initially, 
the powder bed becomes rearranged in order to achieve closer packing. Due to the 
densification, the arrangement becomes more difficult and deformation of particles at 
points of contact begins. This may result in reversible elastic deformation or 
irreversible plastic deformation. If the applied force is greater than the fracture 
strength, the deformation will reach its limits and the particles fragment into smaller 
ones. Eventually, the surfaces of the particles become reduced by bonding and 
consolidation. When compressing dry solid particles, the bonding formation, i.e. the 
strength keeping the tablet intact, is due to the sum of intermolecular forces, solid 
bridges and mechanical interlocking (Alderborn 1996, Nyström and Karehill 1996, 
Property Effect References 
Moisture content and 
relative humidity 
 
The probability of capillary forces increases as a 
function of relative humidity and is likely to 
predominate when it reaches >60 %. Adhesion 
due to moisture content occurs with hygroscopic 
and hydrophilic compounds which have the 
ability to undergo hydrogen bonding. An 
increase in the moisture content may lower the 
surface energetics and electrostatic properties of 
the powder surface. 
 
Eilbeck et al. 2000, 
Murtomaa et al. 2004, 
Nikolakakis et al. 2002, 
Padmadisastra et al. 1994, 
Podczek et al. 1997, Price 
et al. 2002, Sunkersett et al. 
2001, Zeng et al. 2001b 
Electrostatic 
properties 
Opposite electrostatic charges promote 
adhesion. A change in the charge-inducing 
material can produce electrostatic charges of 
different magnitudes. Electrostatic charge is not 
stable: it is sensitive to surface contamination 
and pharmaceutical excipients have low 
resistivity and therefore lose any electrostatic 
charge through earth leakage relatively quickly. 
 
Eilbeck et al. 2000, Mäki et 
al. 2007, Rowley 2001, 
Staniforth 1987, Staniforth 
and Reese 1982 
Mixing time Mixing is an equilibrium event. If continued, 
segregation occurs due to differences in particle 
size, shape or density. 
Davies 2001, Twitchell 
2007, Venables and Wells 
2001 
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Patel et al. 2006, Alderborn 2007). The intermolecular forces are van der Waals 
forces, electrostatic forces and hydrogen bonding. Solid bridges can be regarded as 
contact at an atomic level between adjacent surfaces in the compact material, and 
mechanical interlocking is due to interparticulate hooking of rough surfaces. 
   Although material may undergo a combination of different deformation mechanisms 
during compaction, the powders are classified based on the dominating mechanical 
properties such as elastic, plastic or fragmentation (Nyström and Karehill 1996, 
Hiestand 1997, Patel et al. 2006, Alderborn 2007). Elastic and plastic deformations 
are time independent and the degree of deformation is related to the applied stress. 
Elastic materials tend to regain their original shape as the stress is removed and 
because of these post compaction strength changes, they are not desirable binders. In 
contrast, plastic materials, which undergo permanent changes, exhibit better binding 
properties and have a good ability for solid bridging. Materials, which undergo 
deformation by fragmentation, will create a number of smaller particles which results 
in a large number of interparticulate contact points when fracture strength is achieved 
and therefore these materials are not so sensitive for load dependent changes and less 
prone to undergoing postcompaction strength changes. In addition, there are two 
deformation mechanisms which deviate from the above: reversible viscoelastic and 
permanent viscous deformation, which are dependent of applied stress and the time of 
loading (Nyström et al. 1996, Alderborn 2007). In general, pharmaceutical materials 
tend to undergo a combination of elastic and plastic deformation (Davies 2001). 
   The type of deformation and the formation of the tablet depend not only on the 
physical properties of the materials but also on the rate and magnitude of the applied 
force and the duration of the locally induced stress, which can be controlled by means 
of compaction parameters (Steendam et al. 2001, Patel et al. 2006). An overview of 
the compaction parameters and their impact on the properties of the final tablet is 
presented in Table 4. 
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Table 4. The impact of compaction parameters on formation of tablet. 
Property Effect Reference 
Compaction force Generally, higher compaction force produces 
harder tablets. Compaction force has significant 
importance with materials having elastic, plastic 
and fragmentation deforming properties. High 
compaction force decreases the effects of particle 
size and shape, and, after a certain threshold, 
compaction force does not affect the tensile 
strength of brittle materials, but increases the 
magnitude of solid bridging with plastically 
deforming materials. 
 
Alderborn 2007, 
Fukunaka et al. 2005, 
Nyström and Karehill 
1996, Rudnic and Kottke 
1996, Sun and Grant 
2001a 
Compaction speed The effect of compaction speed is different for 
each formulation, but, in general, changes in 
compaction speed have no significant effect with 
time independent deforming materials. However, 
viscoelastic materials with plastic deformation 
produce stronger tablets with lower speeds and if 
the material can undergo two deforming 
mechanisms, e.g. elastic/fragmentation or 
elastic/plastic deformation, with the first 
becoming predominant as the compaction speed is 
increased. 
 
Davies 2001, Haware et 
al. 2009, Katikaneni et al. 
1995, Marshall et al. 
1993, Roberts and Rowe 
1985, Roberts and Rowe 
1986, Patel et al. 2006, 
Sinka et al. 2009, Tye et 
al. 2005 
Compaction profile A double-sided compaction produces stronger 
tablets. Furthermore, the single compaction 
generates an uneven densification of the powder 
bed during compaction, which may result in 
differences in density and pore structure 
compared to tablets produced by double-sided 
compaction. However, this may not be a 
significant problem in practice. 
 
Busignies et al. 2006, 
Davies 2001, Ellison et 
al. 2008, Muñoz-Ruiz et 
al. 1997, Patel et al. 2006 
Tablet ejection The compacted tablet may adhere to the die wall 
and subsequent ejection may disrupt the tablet’s 
structure, which can affect the drug release. Thus, 
the ejection speed and force may affect the 
magnitude of friction between powder and die 
during ejection. The ejection enables an elastic 
recovery in the radial direction and disruption of 
structure, if material has elastic and fragmentation 
deformation properties. 
 
Davies 2001, Djemai and 
Sinka 2006, Doelker and 
Massuelle 2004, 
Korhonen et al. 2005, 
Sinka et al. 2004b, Sinka 
et al. 2009, Takeuchi et 
al. 2004, Wang et al. 
2004 
Geometry of tooling The various shaped punches generate different 
degree of densification of the powder bed during 
compaction, and subsequently on the density 
distribution of the final tablet, which may result in 
different physical and drug release properties 
despite the equal surface area ratio. However, it 
has been reported that if compaction forces are 
kept equal, the tensile strength of the tablets will 
not vary. A low height/diameter ratio is desirable 
to minimize friction between powder and die. 
Davies et al. 2007, 
Djemai and Sinka 2006, 
Rudnic and Kottke 1996, 
Sinka et al. 2004a, Sinka 
et al. 2009 
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2.6.3 Properties of powder affecting the compaction 
   The compaction parameters and the deformation characteristics are not solely 
responsible of the properties and drug release behaviour of the tablet. In general, the 
discussion attributed with the properties of the powder and tablet strength is 
concentrated to the impact of original particle size and shape (Alderborn 1996). 
However, since the tablet strength is known to be directly proportional to the surface 
adhesiveness, when the particles have the same order of elasticity and plasticity, the 
properties of the powder affecting the strength of the tablet bonding are mostly of the 
same origin as those involved in particulate attraction during powder mixing, which 
was dealt with in previous chapter (Li et al. 2004). Table 5 presents an overview of 
particle and powder properties affecting to the outcome of the tablet.  
   Although the parameters presented in Table 5 have undeniable significance in the 
formation of a matrix tablet and its consequent drug release properties, the concept of 
tablet generation is complicated. Firstly, even small additions of excipients, such as 
lubricants, may have a crucial impact on the behaviour of the powder under 
compression and, thus, on the drug release properties of the final tablet (Dürig and 
Fassihi 1997, Pather et al. 1998, Steendam et al. 2000). Secondly, many parameters 
may have simultaneous effects. This can be exemplified by the following example 
dealing with the moisture content of powder, which can have an ambivalent role in 
tablet formation and on the drug release properties. Steendam et al. (2000) reported 
that the moisture content of matrix forming polymer, amylodextrin, prior to tableting 
and a defined compression force were essential in order to achieve reproducible and 
constant prolonged drug release properties. However, in the case of methyl 
methacrylate-hydroxypropylstarch copolymers, the moisture content of compressed 
powder could alter the drug release of water-soluble drug by inducing its rapid 
dissolution, promoting the weakness of the matrix structure and hence improving its 
partial disintegration (Bravo-Osuna et al. 2008). Thus, the details in Table 5 are best 
regarded as a rough guideline of general trends. 
 
 
40 
 
 
 
Table 5. Powder properties influencing the formation of the tablet. 
Property Effect Reference 
Particle size 
 
In general, small particles, which have an 
increased bonding surface area, yield stronger 
tablets and more homogenous distribution of 
pores. Furthermore, small particles may 
dominate the bonding due to the formation of a 
percolating network. Large particles tend to 
fragment and therefore a change in the particle 
size fraction may alter the deformation 
properties of the materials having tendency 
towards fragmentation and plastic deformation. 
 
Alderborn 1996, Fukunaka 
et al. 2005, Haware et al. 
2009, Li et al. 2004, 
Nyström and Karehill 
1996, Patel et al. 2006, 
Roberts and Rowe 1986, 
Sun and Grant 2001a, 
Twitchell 2007 
Particle shape 
 
Generally, more irregular and rough particles 
yield stronger tablets, but fragmentation 
deforming materials are less sensitive to the 
original particle shape. It is notable that 
different crystal forms exhibit various crystal 
habits and shapes, but the differences in 
tabletability are not due to shape but form. 
 
Alderborn 1996, Fukunaka 
et al. 2005, Nyström and 
Karehill 1996, Patel et al. 
2006 
 
Crystal form Different crystal forms may exhibit different 
compaction characteristics due to varying 
physical properties. It has been reported that 
more stable forms produce weaker bonds and 
polymorphs having slip planes, corresponding 
to greater plasticity in the crystal structure 
produce harder tablets. Generally, amorphous 
forms exhibit plastic deformation and thus 
degree of crystallisation may affect the 
deformation properties. 
 
Feng and Grant 2006, 
Hiestand 1997, Nyström 
and Karehill 1996, Patel et 
al. 2006, Sinka et al. 2009, 
Sun and Grant 2001a, Sun 
and Grant 2001b, Sun and 
Grant 2001c, Wadke and 
Jacobson 1980 
Surface area High surface area confers more possibilities for 
interactions responsible for bonding and thus it 
can be used to affect the drug release properties 
of the preparation. 
 
Fukunaka et al. 2005, Te 
Wierik et al. 1997b 
Surface energy The surface energy of particles may produce 
harder tablets with brittle materials when 
bonding is due to interparticulate attraction and, 
thus, this effect is less significant with 
plastically deforming materials. 
 
Fichtner et al. 2008, Li et 
al. 2004 
Moisture content Moisture content, due to capillary forces or 
facilitation of solid bridging by acting as a 
surface-restructuring medium, can increase the 
tensile strength. In contrast, moisture content 
may act as lubricant by decreasing the tablet 
strength and the density variation within the 
tablet, and surface energy, which decrease the 
friction between the tablet and the die. 
Steendam et al. 2000, Patel 
et al. 2006, Wadke and 
Jacobson 1980 
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2.6.4 Compaction of binary mixtures 
   The properties affecting compaction of powder, such as deformation, are often 
determined using only a single material due to simplify the evaluation. However, 
pharmaceutical preparations seldom consist of only one ingredient and, thus, some 
insight into the behaviour of the binary mixtures will be provided. 
   The binary mixtures can be categorised into three different types, based on their 
densification properties: ductile-ductile, ductile-brittle and brittle-brittle (Fell 1996, 
Majuru and Wurster 1997, Wurster et al. 1999). Many authors have observed simple 
relationships between a mechanical property, such as consolidation behaviour, yield 
pressure or crushing strength, with the mass fraction of the components of the binary 
mixture (Leuenberger 1982, Riepma et al. 1990, Fell 1996, Majuru and Wurster 1997, 
Wurster et al. 1999, Mohammed et al. 2006, Tatavarti et al. 2008). These relationships 
have been especially relevant if the conditions are favourable, e.g. when both of the 
mixture components consolidate by the same mechanism or the mixture consists 
mostly of a single well compactable excipient and one or several poorly compactable 
components (Majuru and Wurster 1997, Kuentz and Leuenberger 2000, Mohammed 
et al. 2006). 
   However, the situation is usually far more complex. The conditions of the powder 
are not always favourable and there have been examples reported, where the 
mechanical property, e.g. tensile strength of the tablet, does not follow the mass 
fraction of the components of the mixture (Vromans and Lerk 1988, Garr and 
Rubinstein 1991, van Veen et al. 2000). Van Veen et al. (2002) and Wu et al. (2008) 
have reported that even a small amount of starch can reduce the tensile strength of the 
sodium chloride tablets, indicating that instead of the mass fraction of the mixture 
components, the volume fraction of the component is more significant. In contrast, 
other studies by Olsson et al. (1998) and Mattsson and Nyström (2000) emphasized 
that the addition of polyethylene glycols (PEGs) can elevate the tensile strength of 
tablets having a greater fraction of sodium chloride, sodium bicarbonate or calcium 
carbonate. The authors deduced that during compaction, the rigid and coarse material 
became fragmented and even a small amount of the relatively ductile material, PEG, 
was sufficient to fill the interparticulate voids, resulting in a creation of strong tablets. 
Thus, it has be concluded that the behaviour of the binary mixtures under compaction 
is a very complex issue and simple theoretical approaches based on studies with only 
single compound are likely to be grossly misleading (Fell 1996). 
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3 AIMS OF THE STUDY  
 
The general objective of this study was to find suitable methods to control the 
structure and subsequent drug release properties of hydrophobic starch acetate (ds 2.7) 
matrix tablets, to relate the structural properties with drug release behaviour, and, 
finally, to evaluate the functionality of in vitro drug release test. The specific aims 
were as follows: 
 
1. To investigate the effects of drug-excipient interactions in a powder blend and to 
determine how this influence the tablet structure and, consequently, the drug release 
mechanism 
 
2. To determine the impact on drug release behaviour of structural changes in a tablet 
caused by crack formation  
 
3. To determine the effect of formulation based parameters and drug compound 
related properties on the drug release rate and to specify the most dominating features 
 
4. To evaluate the functionality and reliability of USP II paddle method by 
visualisation of the diffusion of two physicochemically different drug compounds 
from a hydrophobic matrix tablet 
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4 EXPERIMENTAL 
 
 
4.1 Materials 
 
4.1.1 Starch acetate (I-IV) 
   Potato starch acetate (SA) with a degree of substitution 2.7 (Polymer Corex Oy Ltd., 
Kuopio, Finland) was used as the matrix forming polymer. Starch acetate was sieved 
through vibration sieves (Type 3D, Retsch, Germany) into 5 different particle size 
fractions: < 53 µm, 53–149 µm, 149–297 µm, 297–420 µm and 420–710 µm (I, III) 
or solely through a 710 µm sieve in order to remove larger aggregates (II, IV). 
 
 
4.1.2 Model drugs (I-IV) 
   Anhydrous caffeine (I, II, IV), allopurinol (III), metronidazole (III) and 
salicylamide (III) were all obtained from Sigma-Aldrich (Chemie Steinheim, 
Germany). Acyclovir (III) was obtained from Recordati Industria Chimica E 
Farmaceutica (Milano, Italy), anhydrous theophylline (III) from Oriola (Espoo, 
Finland), paracetamol (III) from Orion Pharma (Espoo, Finland) and riboflavin 
sodium phosphate (IV) Fluka Chemika (Steinheim, Germany). Model drugs were 
usually used as received. However, anhydrous caffeine was sieved through a 710 µm 
sieve in order to separate aggregates (II, IV) and anhydrous theophylline (III) and 
salicylamide (III) (Sigma-Aldrich Chemie, Steinheim, Germany) were ground in a 
mortar in order to reduce their particle sizes. All drugs fulfilled the quality 
requirements of Ph.Eur. 
 
 
4.1.3 Other chemicals (I-IV) 
   Magnesium stearate powder (Orion Pharma, Espoo, Finland) (I-IV) and phenolred 
(II) (Merck, Darmstadt, Germany) were used as received. Chemicals for the 
preparation of dissolution mediums (I, II) and inverse gas chromatography (III) were 
obtained from commercial suppliers and used as received. All materials were at least 
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of analytical grade and, in the case of inverse gas chromatography, HPLC grade or 
equivalent. 
 
 
4.2 Methods 
 
4.2.1 Compound characterisation (I, III, IV) 
   The particle size distributions of drug compounds and sieved starch acetate fractions 
(I, III, IV) were measured by laser diffraction (Mastersizer2000, Malvern Instruments 
Inc., Southborough, MA, USA) using the dry measurement option (Scirocco2000). 
The particle density of drug compounds and SA fractions was measured by a 
pycnometer (MVP-1, Quantachrome, Syosset, NY, USA), using helium as the 
measuring gas. The morphology of SA particles was examined by scanning electron 
microscopy (SEM)-photographs (I), which were taken with a JEOL JSM-35 SEM 
(JEOL, Tokyo, Japan). The specific surface areas of drug compounds and SA 
fractions were determined (BET Flowsorb 2300 II (86-089), Micromeritics Instrument 
Corp., USA) (III).  
 
 
4.2.1.1 Maximum water solubility, dissolution rate and moisture uptake (III) 
   Maximum water solubility of drug compounds was studied by making saturated 
solutions in purified water as the medium (5 UV, Elix, pro-gard 2, Millipore S.A.S., 
Molsheim, France) which were kept at 37 °C and shaken at a frequency of 75 
strokes/min (Grant OLS200, Cambridge, UK) for 68 hours. The solutions were 
filtered (0.45 µm) to remove non dissolved drug particles and the concentrations were 
determined by UV-spectrophotometry (Genesys 10UV, Thermo Spectronic, 
Rochester, USA). The specific wavelengths used are listed in the original paper (III). 
   The dissolution rates of the pure drug compounds were determined by the USP 
basket method, using purified water as the medium (900 ml, 37 °C, 50 rpm). 
Approximately 200 mg of drug compound was placed into a bag, which was made of 
a net with a gap diameter of 15 µm. Three bags containing the drug compound were 
tested individually. The samples were taken from the dissolution bath at 1, 2, 3, 4, 5, 
6, 7, 8, 9, 10, 12, 14, 17, 20, 30, 40, 50 and 60 min. The concentrations were 
determined by UV-spectrophotometry as stated in the original paper (III). When the 
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dissolved amount of drug was plotted as a function of time, the slope of the best fit 
straight line was considered as the dissolution rate. 
   The moisture uptake of the drug compounds was examined by keeping the samples 
in a desiccator for 24 hours at a relative humidity of 100 %. The absorbed moisture 
content of untreated and treated samples was measured by Karl-Fischer titration 
(Mettler DL 35, Greifensee, Swizerland). The percentage of moisture uptake was 
calculated by comparing the moisture content of original and treated samples. 
 
 
4.2.1.2 pH of the solution and degree of ionization (III) 
   The pH of the solutions or, in the case of non-dissolving SA, suspension containing 
each of the compounds was measured (Methorm 744, Methorm Ltd., Herisau, 
Swizerland). The theoretical amount of ionized form of drug compound in presence of 
SA was calculated for weak molecular acids using the Henderson-Hasselbalch 
equations as follows (Eq. 8): 
 
))log(1(
100%
pHpKanti
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a
    (8) 
 
and for weak molecular bases (Eq. 9): 
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4.2.1.3 Inverse gas chromatography (III) 
   The dispersive component of the surface free energy (γSD) of the drug compounds 
was determined by inverse gas chromatography (IGC) (Auto System Gas 
Chromatograph, Perkin Elmer Instruments, Norwalk, USA). The columns used in 
IGC were short glass U-shaped tubes. The hydroxyl groups of glass were deactivated 
by silanation using a 5% (w/V) solution of dimethyldichlorosilane in toluene in order 
to prevent these moieties from reacting with probe gases. After standing for 48 h at 
room temperature, the column was then washed with toluene followed by methanol 
and it was then dried. 
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   The deactivated empty column was filled with approximately 2 g of compound and 
plugged with silanated glass wool. The filled column was stabilised by flowing a 
carrier gas, nitrogen, using approximately 10 ml·min-1 as the flow rate, for 48 h at 30 
°C. An infinite dilution of probe gas was injected into the column to obtain a retention 
time between 30 min and 50 min. Non-polar probe gases used were hexane, pentane, 
octane and nonane, respectively. The values of γSD of drug compounds were 
calculated from the retention times of the probe gasses, determined by a flame 
ionisation detector. The calculated value of γSD was the average of eight individual 
measurements. 
 
 
4.2.1.4 Differential scanning calorimetry (IV) 
   Modulated temperature differential scanning calorimeter (DSC823e, Mettler Toledo 
GmbH, Analytical, Schneezenbach, Switzerland) was used in order to determine 
possible polymorphic changes of caffeine and riboflavin. Temperature and enthalpy 
calibration were carried out with water, indium, zinc and lead. The measurements 
were made in duplicate using a heating rate of 10 °C/min and temperature scale of 
25–300 °C for riboflavin and of 25–280 °C for caffeine. Samples weighing 4–6 mg 
were crimped in 50 µl aluminium pans with holes. A similar empty pan was always 
used as a reference. All runs were performed under an atmosphere of dry nitrogen (50 
ml/min). 
 
 
4.2.2 Powder mixture preparation (I-IV) 
   The powder mixtures were prepared on volume basis and they contained 78 % 
starch acetate and 22 % drug compound (I, II, III, IV) or 80 % starch acetate and 20 
% drug compound (IV). The powders were mixed in a high shear impeller mixer 
(MCM1201EU, Bosch, Stuttgart, Germany) at a mixing time of 4 minutes (I) or 
manually in a geometric series using a card in a mortar with a mixing time of 4 min 
(II, III, IV). The homogeneities of the mixtures were then tested. The mixing time 
was extended gradually, in 2 min steps, the maximum being 8 min, if the desired 
homogeneity was not achieved earlier (II, III, IV). 
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4.2.3 Tablet compaction (I-IV) 
   Tablets were compacted with a compaction simulator (PCS-1, Puuman Ltd., 
Kuopio, Finland) to produce cylindrical tablets with a diameter of 13 mm (I-IV), the 
weights of tablets being 500 mg. The powder was poured into the die and overflowing 
powder was gently collected into die, which was manually prelubricated with 
magnesium stearate using a brush. A sine wave compaction profile was used for the 
upper punch, while the lower punch was kept stationary. The compaction properties 
of the powder were variable as different drug compound or particle size fractions of 
SA were used. Therefore, a wide range of amplitudes was applied in order to generate 
different compaction pressures. The compaction pressures with the respective tablet 
porosities are described in more detail in the original papers (I-IV). The average 
compaction speed was 4 mm·s-1 and the ejection time was always 1.8 s. After 
compaction, the tablets were stored over silica for at least 14 hours before any further 
procedures, such as the dissolution test. In addition, tablets of SA having different 
particle size fractions and caffeine were also compacted and treated in a similar way 
as described above (I). 
 
 
4.2.4 Tablet characterisation (I-IV) 
   The porosity of the tablet was determined by mercury intrusion porosimetry (I) 
(Micromeritics, Model Autopore 9220, Norcross, GA, USA). Sufficient amounts of 
tablets were used for each particle size distribution and porosity in order to obtain a 
sufficient change of mercury in the penetrometers, and thus an accurate measurement. 
The pressures applied in the low-pressure and high-pressure domains were from 7 to 
171 kPa and 0.2–370 MPa, respectively. These pressures correspond to pore sizes 
ranging from 220 to 0.004 μm. The contact angle of mercury with starch acetate and 
caffeine was assumed to be 140° and the surface tension of mercury 480 mN·m−1. 
Otherwise the porosity (ε) was determined on volume basis as follows (II, III, IV) 
(Eq. 10): 
 
V
V01%100      (10) 
 
48 
 
 
 
where V0 is the theoretical volume of the tablet, based on the mass of the tablet and 
the densities of the tablet composites, and V is the measured volume of the tablet, 
which is based on the dimensions of the tablet. 
   The fracture/yield strength of the single materials and sieve fractions were analyzed 
from their densification profiles according to Heckel (1961) (I). Scanning electron 
microscopy (SEM)-photographs were taken of the surface and the cross-sections of 
both room temperature stored and freeze-dried tablets after 6 hours of dissolution 
testing in order to confirm that freeze drying had not altered the morphology of the 
tablets (II). 
 
 
4.2.4.1 X-ray computed microtomography (unpublished) 
   The X-ray computed microtomography is based on the different absorption 
coefficients for X-rays in different materials, such as tissues. This technique was 
originally devised for medical imaging: it has been routinely applied to the non-
destructive analysis of bone structures in the clinics, e.g. after fractures (Stock 1999, 
Neues and Epple 2008). The development of powerful but miniaturised X-ray sources 
has resulted in a technique called X-ray computed microtomography, the principle of 
which has been described by many authors (Farber et al. 2003, Yang and Fu 2004, 
Neues and Epple 2008, Zeitler and Gladden 2008). Data for one slice in the xy plane 
are acquired at different angles. The object is moved in the z-direction and the process 
is repeated until the area of interest has been covered. The three-dimensional image is 
obtained by stacking the corresponding slices on top of each other and the subsequent 
reconstructing of the data using mathematical algorithms. The utilization of X-ray 
computed microtomography in the field of pharmaceutics has barely started, but in 
recent years some successful experiments have investigated compaction of the 
powder, density variations within a tablet and void formation during dissolution 
(Sinka et al. 2004a, Busignies et al. 2006, Fu et al. 2006, Karakosta et al. 2006, Zeitler 
and Gladden 2008).  
   The structure of the tablet was determined by computed microtomography 
measurements (Skyscan 1172 X-ray Micrograph, Skyscan N.V., Aartselaar, Belgium). 
The tablets were placed on a rotary turntable with their radius in the horizontal 
direction. The data was collected using 100 kV voltages, 0.5 mm thick aluminium 
filter and by rotating the tablet 0–360°. The angular increment used in these scans was 
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0.68° and at each angle, ten radiographic images were averaged. The pixel size 
achieved with this setup was approximately 22.5 µm. 
 
 
4.2.5 In vitro dissolution testing (I-IV) 
   Drug release from tablets was determined by the USP II paddle method (AT6 and 
AT7, Sotax, Basel, Switzerland) at 75 rpm. The dissolution medium (900 ml, 37 ± 0.5 
ºC) was phosphate buffer (pH 6.8) (I, II) or purified water (III, IV). Detailed 
information about sampling times is given in the original papers. The concentrations 
of drug samples taken were determined by UV-spectrophotometry (Genesys 10UV, 
Thermo Spectronic, Rochester, USA) at wavelengths given in the original papers (I-
IV). 
 
 
4.2.6 Freeze drying and tablet processing (II, IV) 
   Three tablets were taken out from the dissolution vessel at each measurement time 
point, directly frozen at –70 ºC and then freeze dried (ModulyoD, Thermo Savant, 
Rochester, USA) to remove the dissolution liquid by sublimation. It was assumed that 
freezing of tablets at –70 ºC would stop almost instantaneously the movement of 
liquid in the tablet. 
   After the freeze drying the tablets were cut axially into two pieces (Isomet Low 
Speed Saw, Buehler, Lake Bluff, USA) using a 0.3 mm thick diamond blade. 
 
 
4.2.7 Calculation of molecular descriptors (III) 
   For molecule description calculations, two different molecular modelling software 
packages were used (Material Studio version 4.2, Accelrys, San Diego, CA, USA, and 
VolSurf version 4.1.4.3, Molecular Discovery, Middlesex, UK). Molecule structures 
were first sketched using the Material Studio software package. Sketched structures 
were minimized using the Forcite toolbox with the COMPASS force field and force 
field assigned charges. A smart minimization algorithm was used with following 
convergence tolerances: energy 10e-4 kcal/mol, force 5e-3 kcal/mol/Å, and 
displacement 10e-5Å. A first set of molecular descriptors was calculated using the 
Material Studio QSAR toolbox. In addition, VolSurf descriptors were calculated using 
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the default calculation settings. The procedure described above yielded 158 molecular 
descriptors for each molecule. It was essential to use different software packages and 
force fields since the molecular descriptor based approach to explain drug release is 
novel and there wasn’t any prior information on which software package, descriptors, 
or force fields would yield the best data for the purpose in question. 
 
 
4.2.8 Multivariate data analysis (III) 
   Traditionally in the field of chemometrics, which can be defined as the acquisition 
of the data and the extraction of useful information from that data, the nature of 
analysis method has been univariate, i.e. one signal is proportional to the 
concentration of the analyte (Deming 1986, Forina et al. 2007). However, the 
information available has clearly increased in recent years due to more and more 
efficient measurement techniques and computational resources and thus the emphasis 
of the chemometrics has been transferred from classical univariate into multivariate 
analyses (Olivieri 2008). Basically, instead of the determination of the analyte from 
complicated spectroscopy data, the multivariate data analyses can be exploited in 
situations when there are complex data matrices to be interpreted or their relationships 
clarified. Thus, in the field of pharmaceutics, where the relationships of composition 
of the formulation, powder mixing and compaction, and tablet formation and 
subsequent drug release mechanism and rate are the focus of interest, the multivariate 
analysis methods, such as principal component analysis (PCA) and its regression 
extension partial least squares to latent structures (PLS), has been utilized (Adams et 
al. 2001, Gabrielsson et al. 2002, Korhonen et al. 2005, Gabrielsson et al. 2006, 
Haware et al. 2009). The objective of PCA is to describe the variation in the data 
matrix, X, with a minimum of variables (Gabrielsson et al. 2002). In addition, PLS 
takes a step forward and it is a method of modelling two data matrices, X (variables) 
and Y (observations) and to establish the relationship between them (Wold et al. 
2001). 
   Due to the complex nature of the data, i.e. the large number of formulations and 
properties of drug compounds, the PLS was used as a regression extension of PCA 
(SIMCA-P, Version 11.0, Umetrics AB, Umeå, Sweden). In this case, the X-matrix 
consists of explanatory variables, i.e. formulation and powder blend parameters, and 
both the measured and the modelled drug properties. The Y-matrix (observations) 
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consists of the various percentages of the released amount of drug at given time 
points. Data was pre-treated using unit variance scaling and mean centering in order 
to normalize the weight of each variable in the model. Then, the observations were 
divided into a training set and a test set by excluding approximately every second 
observation. The training set was used to evaluate the validity of model. The sizes of 
training and test sets were 141 and 121 observations, respectively. 
   The models were generated from three different observation sets: time points from 0 
- 45 min, 60 - 1200 min, and 0 - 1200 min, which covered all the measurement points. 
In model building, insignificant variables can be detected according to the coefficient 
and variable importance plots. The other models were created by temporarily 
eliminating variables by choosing them on the basis of the coefficient plot, and the 
other models by choosing them on the basis of the variance important plot. If the 
value of prediction parameter (Q2) was seen to have subsequently increased without 
the newly removed variable, it was then permanently removed. This procedure was 
repeated until the Q2 parameter did not improve or change any longer. The possible 
strong outliers were determined by Hotelling's T2 diagnosis at the 95% confidence 
level. 
 
 
4.2.9 Fourier transform infrared spectroscopy, mapping and data processing 
(IV) 
   Infrared (IR) spectroscopy is based on the absorption of IR light by molecular 
vibration when the frequencies of light and vibration coincide, and it has been 
routinely used as an identification assay (Bugay and Findlay 2001, Barth and Zscherp 
2002). Although the basis of the Fourier transform infrared (FTIR) imaging was 
developed as early as in 1949, due to rapid developments in this technique, this 
method has become increasingly popular in recent years (Wetzel and LeVine 1999, 
Bugay and Findlay 2001). This method for obtaining non-invasive information 
usually from the surface of the sample is often attributed with the term imaging, 
although there are three different approaches for the data acquisition: point mapping, 
line imaging and focal plane array (Levin and Bhargava 2005, Gendrin et al. 2008). In 
point mapping, a spectrum is measured at one position, after which the sample moves 
to the next measurement point on the grid, where the measurement occurs, until the 
desired area is scanned. Line imaging resembles point mapping, but instead of several 
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individual measurement points, the spectrum is collected continuously as a line. Focal 
plane array consists of several thousand elements forming a matrix of pixels, which 
enables the acquisition of thousands of spectra at the same time. FTIR spectroscopy is 
suitable for various situations in the field of pharmaceutics, since it can distinguish 
not only different compounds, but it is also sensitive enough to determine even small 
changes, such as different polymorphic forms (Barth and Zscherp 2002). Thus, FTIR 
with imaging options is suitable for use in solid dosage form studies and it has been so 
far utilized for evaluating homogeneity, stability and lately even drug release 
behaviour issues (Markovich et al. 1997, El-Hagrasy et al. 2001, Coutts-Lendon et al. 
2003, Kazarian and Chan 2003, Lee and Lin 2004). 
   In order to obtain the characteristic peaks of the model compounds, i.e. anhydrous 
caffeine, riboflavin sodium salt and SA, the spectra of pure compounds were 
determined by the attenuated total reflectance (ATR) (Nicolet 8700 FT-IR, Thermo 
Nicolet, Madison, USA) using a diamond crystal and wavenumbers from 2000 cm-1 
up to 600 cm-1. Resolution was 1.0 cm-1 and the number of measurements was 64. 
   Fourier transform infrared mapping of the cross-section surfaces of the tablets 
removed from the dissolution bath was performed by ATR (Spectrum Spotlight, 
PerkinElmer, Beaconsfield, UK) using a germanium crystal. The wavenumbers used 
ranged from 2000 cm-1 up to 600 cm-1 with a resolution of 1 cm-1 with the size of one 
pixel being 100x100 µm2. The number of scans was four since this produced spectra 
with practically no noise. The measurements were carried at a temperature of 22 °C 
and the area contained 6 pixels in the radial and approximately 30 pixels in the axial 
direction, as presented in Figure 4.  
 
 
 
 
 
 
 
 
 
Figure 4. Schematic showing the scanned region of the tablet. 
 
Tablet Scanned area
6 pixels
30
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   The interpretation of spectra may be difficult, since there are overlapping bands, 
shifting baselines and other artifacts, which are due to rough surfaces of the sample, 
optical effects, and detector noise (Bhargava and Levin 2001, Levin and Bhargava 
2005, Gendrin et al. 2008). Therefore, in this case, the second derivative of the spectra 
was obtained and the band of the characteristic peak of the compound in question was 
used in the image generation. This procedure eliminated the effect of baseline shifting 
and allowed more sensitivity in selecting peaks from the complex absorption, but, 
however, it did increase the noise (Stuart 2004, Gendrin et al. 2008). The data 
processing and image generation for analysis were done with Spotlight Software 
(version 1.0.1, PerkinElmer Instruments LCC, Shelton, USA). 
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5 RESULTS AND DISCUSSION 
 
 
5.1 Powder and mixture characterisation (I) 
   The starch acetate particle size fractions consisted of particles having fairly round 
shapes and smooth surfaces (Fig 5a). The powder characteristics are presented in 
Table 6. The density of starch acetate particle decreased with increasing particle size. 
A cross-section of a starch acetate particle shows large holes inside the particle (Fig. 
5b). These encapsulations are inaccessible to helium gas intrusion during pycnometry 
measurements and are responsible for the lower measured particle densities compared 
to that of milled starch acetate (Table 6). The measured density of milled starch 
acetate can be regarded as a more accurate estimation of the true material density, and 
this is used in the further calculations. As for most drugs, the particle size of caffeine 
is small compared to most SA particle size fractions. 
 
 
 
 
 
 
 
 
Figure 5. SEM photographs of starch acetate: (a) an intact 297-420 m SA particle 
and (b) cross-section of a 297-420 m SA particle. 
 
 
Table 6. Physical characteristics of starch acetate sieve fractions, caffeine and their 
mixtures. 
Material Sieve 
fraction 
(µm) 
Pycnometric 
particle density 
(g/cm3) 
Volume mean 
particle size 
(µm) 
Fracture 
strengtha 
(MPa.) 
Carrier 
payload 
SA/Caffeine 
starch acetate   53 1.341 11 63b 0.06 
 53-149 1.341 110 48 0.59 
 149-297 1.367 265 47 1.44 
 297-420 1.324 396 50 2.09 
 420-710 1.311 542 53 2.83 
 milled 1.425    
caffeine - 1.404 11 90b  
a Fracture strength was calculated as an average value in the range of the compaction pressures used.  
b viscoelastic densification. 
b)a)
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   As pointed out in the review of the literature (chapter 2.5.1), depending on 
differences in particle size, surface morphology and surface energy, powder mixtures 
can have different organisations. Thus, if one cannot determine the surface energy, it 
can be assumed that the micronised drug particles adhere onto the larger SA particles 
forming an ordered mix (Barra et al. 1998). However, when the smallest SA fraction 
is used, a random type mixture is obtained.  
   Although Barra et al. (1998, 1999) noted that the increase in the difference in 
particle size causes the more frequent interaction, the interaction frequency cannot 
take into account the total amount of drug and carrier particles in a blend, especially 
when all carrier surfaces are completely occupied. In the calculation of the coverage 
of carrier particles by all drug particles, the following assumptions made by Dickhoff 
et al. (2003) were applied: firstly, all particles of each compound are spherical and 
monodisperse with a diameter that equals the volume mean particle size obtained by 
laser diffraction measurements; secondly, the projection of each drug particle on the 
carrier surface is a square with a side that has the same length as the diameter of the 
particle.  
   Since the particles of SA fulfill these assumptions, the carrier payload (CP), i.e. the 
ratio between the total projection surface area of drug particles and the total outer 
particle surface area of SA, can be calculated as follows: 
 
SASAmean
ledrugparticledrugparticmean
Nd
Nd
CP 2
,
2
,     (11) 
 
where dmean is the mean particle size of the compound and N is the number of particles 
in the mixture. It is notable that the utilization of CP does not automatically give exact 
knowledge of the organization of the powder, since there are strict requirements for 
properties of the powder components, as described above. However, despite the 
restrictions, CP can still be thought to give an adequate estimation of the organization 
of the powder mixture. Table 6 gives the calculated carrier payloads for the different 
SA particle size fractions and caffeine. Although a mixture containing the smallest 
particle size fraction of SA is to be considered as a non-interactive mixture, the carrier 
payload is still a good indicator of SA surface occupation within this mixture. A 
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carrier payload exceeding 1 indicates that the complete outer particle surface area of 
SA is covered by caffeine particles with no free SA surface area available. 
   SA deforms partially by fragmentation and plastically, and has lower fracture 
strength than viscoelastically deforming caffeine (Table 6). Therefore, in all particle 
size fractions, SA particles fracture at an earlier stage during compaction than caffeine 
particles, which can be used in order to estimate the structure of the tablet. When the 
powder is compressed, the unoccupied surfaces of SA, in powders having CP lower 
than 1, have possibilities to bond with each other and establish a continuous network, 
i.e. percolate. In contrast, with powders having greater value of CP, a higher 
densification is necessary to overcome the SA-drug bonding and obtain SA-SA 
bindings. 
 
 
5.2 Pore size distribution in tablets compressed from blends (I) 
   Tablets compressed from binary mixtures can be regarded as three-component 
particulate systems containing not only excipient and drug but air, which is 
considered as porosity. As discussed in the review of the literature (chapter 2.4), the 
porosity plays important role in drug release behaviour of the matrix preparation. 
Tablets from each SA fractions containing caffeine were compacted to achieve 
porosities 12, 15, 20, 22 and 25 %. The calculated porosities corresponded to mercury 
intrusion measurements, which confirmed that all pores were interconnected and 
formed a percolating network. Furthermore, the initial particle size distribution of a 
blend determines the pore size distribution between particles in a tablet structure. 
However, for brittle materials, particle fragmentation will partially eliminate the effect 
of particle size over a certain particle size range. Since SA exhibits fragmentation, no 
large differences were found between the pore size distributions of different SA 
particle size fractions at equal tablet porosities.  
   The walls of the pores can consist of different materials: only drug, excipient as well 
as drug, or only excipient. The consistency of pores is important, since the capillary 
force is related to the contact angle between the medium and pore wall material and, 
thus, the pore wall material determines the medium penetration rate. The pore wall 
construction depends on the particle packing in the tablet structure and it can consist 
only of drug particles when the drug particles form a percolating network throughout 
the tablet. To determine whether or not a drug percolating matrix existed in a tablet 
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structure, the pore size distributions of tablets compressed from SA/caffeine blends 
were compared with the pore size distribution of tablets compressed from pure SA 
and caffeine at equal porosities. Tablets compressed from pure caffeine showed 
particular pore sizes between the caffeine particles for each tablet porosity and no 
similar pores were found in tablets compressed from pure SA particles, as can be seen 
from Figure 6a. When caffeine particles are not able to form pores between 
themselves, no extra pores of similar size can be seen from tablets compressed from 
blends (Fig. 6a). In other tablets, especially when the value of CP is greater than 1, 
extra pores were found and these had the same size as those in caffeine tablets, which 
is an indication of the existence of a caffeine matrix in tablet (Fig. 6b). Caffeine 
matrices could be distinguished in tablets compressed from SA particle size fraction 
53-149 µm with tablet porosities of 20 % and higher, and in tablets prepared from the 
three largest SA fractions with porosities of 15 % and higher. 
 
 
 
Figure 6. Pore size distributions of tablets, measured with mercury intrusion 
porosimetry, consisting of (◊) 80% 149-297 m SA and 20% caffeine, (□) 100% 149-
297 m SA and (∆) 100% caffeine with equal tablet porosities of (a) 12% and (b) 
22%. 
 
 
5.3 Relation between tablet behaviour and drug release (I) 
   Tablets compressed from the different mixtures showed variable behaviours during 
dissolution tests. The characteristic changes in physical appearance during dissolution 
could be classified into three different groups: appearance of cracks, surface erosion, 
and rapid tablet disintegration. The physical appearances of tablets, which were strong 
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enough to be removed from the dissolution bath after 24 h dissolution test, are 
presented in Figure 7a and a corresponding scheme classifying the same phenomena 
is presented in Figure 7b. As an example of the effect of different tablet behaviour 
during in vitro dissolution test on drug release, the drug release profiles of tablets 
compressed of SA/caffeine blends containing SA particle size fraction of 149-297 µm 
and with different porosities are presented in Figure 8. 
 
Figure 7. (a) Tablet shapes after the 24 hour dissolution test. SA particle size 
fractions: upper row < 53 m, middle row 53-149 m and lower row 149-297 m. 
Other tablets were too weak to be recovered from the dissolution vessels. 
(b) Schematic representation of different tablet behaviours during drug dissolution 
tests: tablet cracking, tablet erosion and tablet disintegration. Variables are the initial 
tablet porosity (x-axis) and SA particle size fraction (y-axis). The grey background 
indicates the presence of a caffeine matrix in the tablet, as detected by mercury 
intrusion porosimetry. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Percentage of caffeine released from tablets compressed from 149-297 m 
SA as a function of time. Initial tablet porosities are 12% (◊), 15% (□), 20% (∆), 22% 
(×) and 25% (○). Standard deviations are given as error bars (n=3). 
a)
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   By investigating Figures 7 and 8, it can be concluded that tablets exhibiting strong 
prolonged release properties maintain their shape and show only formation of cracks, 
and have low variation in the drug release rates. This is typical for those tablets that 
contain only a SA matrix in the structure. In contrast, a tablet containing a caffeine 
matrix (according to mercury porosimetry), which is indicated by the grey area in 
Figure 7b, allows rapid penetration of water into the tablet, which in the case where 
only a caffeine matrix exists results in rapid disintegration of the tablet. When a 
caffeine matrix coexists with a percolating SA matrix, surface erosion is observed, 
which results also in prolonged drug release properties but with more variation in 
drug release rates. Overall, the results from the range of tablets where mercury 
porosimetry detected the existence of a caffeine matrix are in a good agreement with 
the observed tablet behaviour during dissolution tests. Thus, the SA matrix prediction 
by CP is strengthened by the absence of tablet disintegration, i.e. tablets stay intact 
and exhibit crack formation or show slow erosion. 
 
5.4 Liquid penetration into matrix tablet (II) 
   The formation of cracks is typical with tablets having a percolating network that 
consists of SA. The same phenomenon has been observed with another hydrophobic 
polymer, amylodextrin (Steendam et al. 2000). The formation of cracks alters the 
structure of the tablet, which undoubtedly has an effect on the drug release properties. 
Thus, the formation of cracks was studied in more detail. Since the formation of the 
crack occurs during the in vitro dissolution test, it can be assumed that it is a result of 
liquid penetration, so the liquid penetration was determined using cylindrical tablets 
compressed from SA/caffeine blend into a porosity of 12 %, containing a colour 
indicator. 
   The radial and axial liquid boundary movements in tablet are shown in Figure 9. 
Data points are shown only up to 360 min, because the tablets had become completely 
wetted at 480 min. The radial movement in the tablets followed first order kinetics up 
to 120 min, after which there was an abrupt, but constant, increase in the movement 
and then it started to proceed linearly as a function of time. The axial liquid boundary 
movement followed also first order kinetics up to 120 min, subsequently it also started 
to proceed linearly as a function of time. The sudden acceleration observed in radial 
liquid boundary movement may well be associated with the changes occurring in the 
tablet structure in the radial direction. 
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Figure 9. The axial (■) and radial (□) liquid boundary movements in cylindrical 
tablets as a function of time. Standard deviations are given as error bars (n=3). 
 
 
5.5 Tablet geometry changes and crack formation (I, II and unpublished) 
   As the liquid boundary proceeds inside the tablet, it starts to expand mainly in an 
axial direction due to water absorption. This phenomenon is recognized as tablet 
expansion. As the expansion proceeds, the solid structures of the tablet start to 
disintegrate and visible cracks are generated in the radial side of the tablets. This 
phenomenon is known as cracking. The tablets examined here showed expansion and 
cracking during the dissolution process, but the expansion of matrix in the radial 
direction was insignificant. 
   The extent of the expansion and consequently, crack formation can be measured 
using the percent of expansion (Et%) which is calculated as follows: 
 
%100%
before
t
t H
HE      (12) 
 
where Ht is the height of the cylinder measured of the edge of the tablet after the 
dissolution test and freeze drying and Hbefore is the height of the cylinder of the tablet 
before the dissolution test. The percent of expansion for the cylindrical tablets as a 
function of time is shown in Figure 10. 
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Figure 10. The percentage of expansion for cylindrical tablets as a function of time. 
Standard deviations are given as error bars (n=3). 
 
 
   It can be seen from Figure 10 that the tablets started to expand almost immediately, 
when immersed into the dissolution medium. However, the first visible cracks in the 
middle of the faces of the cylinder of the tablets became apparent after 2 hours as the 
Et% reached approximately 110 %. This phenomenon can also be seen in the liquid 
boundary movement: there was an abrupt change in the radial liquid boundary 
movement speed at 2 hours (Fig. 9). Thus, it can be concluded that the structure of the 
tablet changes dramatically as the expansion proceeds up to an Et% of 110 %. 
   Although the expansion had reached its apparent maximum within 8 hours (results 
not shown), the geometry changes within the tablet were not over. This was examined 
by X-ray computed microtomography with tablets at time points of 0, 4, 8, 14 and 24 
h. The images generated by this method are presented in Figure 11 and quantitative 
information derived from the same data is presented in Table 7. While investigating 
Figure 11 and Table 7, some sources of deviation have to be discussed. Firstly, the 
resolution of method was approximately 22.5 µm and therefore, the smallest 
structures, such as pores, were not detected. Thus, in Table 7, the tablet at time point 
of 0 h seems to have a porosity of 0 %, although when calculated on the basis of 
equation (10), which produces almost identical results as accurate mercury intrusion 
porosimetry in chapter 5.2, the result was approximately 13 %. Secondly, although the 
method is able to define areas having different densities, such as matrix and drug 
compounds, in this particular case, the densities of tablet components were too close 
to each other and therefore, only air resulting from dissolution, expansion and 
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cracking could be confidently detected. Thirdly, the tablets tend to curve at the edges 
due to expansion and cracking (as shown in original paper II in Fig. 4a). This curved 
area was not taken into the analysis when Table 7 was generated, since it would have 
been time consuming and produced inaccurate data. Therefore, the data, especially at 
time points of 14 and 24 h, may not be accurate in terms of porosity, but still be a 
good estimation of the structure of the tablet at given time points. 
   By investigating Figure 11, it can be seen that as dissolution proceeds as a function 
of time, the pores are generated within the matrix. The diameter of a pore (diameter of 
approximately 10 pixels being equivalent to 225 µm) corresponds with the largest 
drug particles, since according to laser diffraction measurements, the diameter of 10 
% of all drug particles were larger than 215 µm. Therefore, it can be assumed that the 
visible pores in the X-ray computed microtomography images were generated due to 
drug particle dissolution. In addition to formation of pores and cracks, there are small 
cavities or tunnels present. They might be due to the dissolution of small particles 
between the matrix forming agent as at the time point of 4 h, or an extension or 
preliminary stage of crack as especially at time points of 8, 14 and 24 h, where they 
extend even into the middle of the tablet. Finally, some tunnels, at the interface where 
pores change into solid tablet, seem to be slightly wider, entrapping an area having the 
same size as the pore. These might be drug particles in the middle of the dissolution 
process. 
 
 
 
Table 7. The quantitative information of cylindrical tablets’ geometry changes during 
dissolution test on basis of X-ray computed micro tomography. 
 Time point (h) 
Parameter 0 4 8 14 24 
Total tablet volume (mm3) 306.9 412.2 413.3 420.9 420.9 
Number of pores 0 2391 2922 3115 4486 
Pore surface area (mm2) 0 609.8 980.4 1392.8 1574.2 
Pore separation (mm) - 2.1103 1.4968 1.1165 0.89076 
Volume of pores (mm3) 0 18.6 35.0 50.2 50.1 
Total porosity % 0 4.5 8.5 11.9 11.9 
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Figure 11. The X-ray computed micro tomography cross sections of cylindrical 
tablets. The density is presented as a function of color: less dense parts, such as air, 
are black and more dense areas are lighter. 1. Pore. 2. Crack. 3. Tunnel due to 
dissolution of small particles between matrix forming agent. 4. Tunnel as an extension 
of crack. 5. Partly dissolved drug particle. 
 
 
   The information in Table 7 supports the findings that the changes of tablet were not 
over although the expansion has reached its maximum. As the dissolution of drug 
compound, expansion and cracking proceeds, the total volume of tablet expands. 
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Furthermore, the number of individual pores, volume of pores, pore surface area, total 
porosity and pore separation, which can be regarded as the parameter describing the 
distance of the pores, all increase. Thus, it can be concluded on the basis of Table 7 
that although tablet volume at time points of 14 and 24 h seems to be equal, the 
number of pores is greater and they are situated more closely than in tablets of earlier 
time points, which can be regarded as proof of structural changes. 
   The reason for expansion and crack formation can be sought from the compression 
and consequent internal structure of the tablets. Tablets are complex systems, which 
consist of inter (between drug and matrix compound particles) and intra (between two 
matrix compound particles) particulate bonds, where the energy generated during the 
compression is stored (van der Voort Maarschalk et al. 1996). The penetrating solvent 
molecules occupy the positions between the molecules and drug compound particles 
which reduce the secondary inter- and intra-molecular bonding forces (Narasimhan 
2001, Callister 2000). SA, that has a ds value as high as 2.7, is virtually in an 
amorphous and glassy state (Korhonen et al. 2000). Therefore, during the dissolution 
process, the interaction with water may lower the glass transition temperature of the 
starch acetate and the polymer transforms from a glassy, rigid configuration into 
rubbery state with an increase in elastic energy. Thus, because of these two processes, 
the stored energy generated during compaction is released and this is reflected as 
expansion, which ultimately leads to cracking (Callister 2000) 
 
 
5.6 Effect of crack behaviour on drug release (I, II and unpublished) 
   On basis of the equation (3) and the results shown in chapter 5.3, it can be stated, 
that drug release is controlled by the tablet’s structural properties, such as porosity 
and tortuosity of the capillary system. These properties are altered as the dissolution 
proceeds and the geometry of the tablet changes. Thus, it can be concluded that the 
crack formation can have a great impact on drug release behaviour. 
   The plot (and equation in the figure legend) describing the fraction of released 
caffeine as a function of the percent of the expansion is presented in Figure 12. A 
linear correlation was obtained between the cracking and the release of caffeine with 
cylindrical tablets over the experiment, i.e. up to 8 hours (time points are not shown in 
the Fig. 12). The linearity could be due to continual crack formation promoting the 
drug release. The rate of drug release decreases as the cracking reaches its maximum, 
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this being reflected in a lack of correlation at 24 hours (time point is not shown in the 
Fig. 12). The diffusion path for the drug compound does not any longer shorten as 
radically after the crack formation has reached its maximum, although there is a 
generation of tunnels according to the data in Figure 11.  
 
 
 
 
 
 
 
 
Figure 12. The fraction of released caffeine as a function of percent of expansion. 
The equation for describing the drug release as a function of expansion percentage at 
time scale of 0–480 min (y = 2.4104x – 244.95) has a correlation coefficient (R2) of 
0.9945. Standard deviations are given as error bars (n=3). 
 
 
   The effect of expansion and crack formation on drug release is a chain reaction. The 
tablets start to expand due to polymer relaxation as the liquid penetrates into the 
matrix. Cracks continue to be generated until the expansion proceeds up to the point 
where Et% is 110 %. Crack formation shortens the length of the diffusion path and 
decreases the total tortuosity. This promotes drug release and the liquid can penetrate 
deeper into the matrix. It seems that the structure of tablets change dramatically as the 
cracking proceeds. 
 
 
5.7 Drug release kinetics from tablets with continuous porous networks (I) 
   The caffeine release profiles up to 60% from porous SA tablets depicting cracking 
and erosion with porosities higher than 10% were fitted by Equation (7). The 
diffusional and relaxational drug release rate coefficients are represented in Figure 
13a and 13b, respectively, as a function of the initial tablet porosity. Although the 
diffusional and relaxational coefficients cannot be compared directly due to the 
different exponents of the units, the comparison between Figure 13a and 13b depicts 
some pronounced alterations. For tablet porosities lower than 20%, the difference in 
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caffeine release is primarily the result of changes in krelaxation (Fig. 13b). When the 
tablet porosity exceeds 20%, kdiffusion plays a more important role in the changes of the 
caffeine release rate (Fig. 13a). As they are parallel processes, water penetration and 
drug diffusion at higher tablet porosities predominate over the contribution made by 
the relaxational release mechanism. 
 
 
Figure 13. (a) kdiffusion and (b) krelaxation of caffeine released from SA tablets as a 
function of initial tablet porosity. SA particle size fractions are < 53 m (◊), 53-149 
m (□), 149-297 m (∆), 297-420 m (×) and 420-710 m (○). 
 
 
5.8 Characteristics of model compounds (III) 
   The characteristics of the compounds used in determining the most important 
formulation parameters and drug compound properties considering the drug release 
rate from hydrophobic matrix tablet are presented in Table 8. The drug particles seem 
to display almost identical physical properties, which are crucial according Noyes and 
Whitney's definition of solubility as stated in Equation (1). However, acyclovir and 
salicylamide stand out as exceptions. Acyclovir has a small mean particle size and a 
large specific surface area, whereas salicylamide has a slightly larger particle size and 
a small specific surface area. According to the behaviour of drug particles used in this 
study, maximum water solubility seems to correlate well with the dissolution rate 
(results not shown). However, the anhydrous form of theophylline is an exception: it 
has a greater dissolution rate compared to the maximum water solubility and it 
exhibits higher percentage of water uptake. These findings might result in faster drug 
release. It is notable that all the compounds are practically unionized in the presence 
of SA (pH of SA suspension was 6.89). In conclusion, the water solubility and 
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dissolution rates of all the compounds, and, consequently, the predicted order of drug 
release according to Higuchi (1963), from greatest to lowest are as follows: 
paracetamol, theophylline and metronidazole, salicylamide, acylcovir and allopurinol. 
 
 
5.9 Powder organisation and tablet structure (III) 
   Small drug particles can adhere on the surface of SA particles, if certain conditions 
are fulfilled, as dealt in the review of the literature. Results indicate that SA has great 
surface energy due to the fact that it absorbs probe gases during inverse gas 
chromatography measurements and, more importantly, the mean particle size of the 
matrix compound for every size fraction used is substantially larger than those of the 
drug substances. Thus, the drug particles adhere onto the surface of SA and the 
arrangement of the powder blend and, consequently, the predicted theoretical 
structure of the tablet can be described by using CP as discussed earlier in chapter 5.1. 
   The calculated CP values of powder mixtures containing each drug compound and 
different particle size fractions of SA are presented in Table 9. As before, in powders 
having CP lower than 1, the SA particles have possibilities to bond with each other 
and establish a continuous network. It is notable that when the value of CP is 
approximately 1 or higher, the formation of percolating matrices are highly dependent 
on the deformation properties of the SA and the drug compound in question and, 
therefore, on the compaction pressure used. However, this was not taken directly into 
account, since CP has been shown to provide a good estimation of the structure of the 
tablet. In addition, the properties affecting the structure of the tablet, i.e. particle size 
fraction of the SA and the porosity the tablets, were standardized, and the variance 
caused by compaction pressure was included in the subsequent analyses. 
   By investigating Table 9, it can be concluded that the drug release controlling 
matrix of SA is generated with SA fractions of < 53 µm and 53-149 µm. Acyclovir 
stands out again as an exception: a CP value of 0.98 with SA fraction of 53-149 µm is 
close to the critical value of 1, but release is theoretically controlled by a single matrix 
of SA. Salicylamide is another exception: CP value of 1.05 with a SA fraction of 149-
297 µm indicates that the tablets likely consist of two matrices and drug release might 
still be partially controlled by the SA matrix. However, when SA fractions of 297-420 
µm and 420-710 µm are used with salicylamide, on the basis of CP, the drug release 
controlling SA matrix should not be present. 
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5.10 Tablet behaviour and drug release (III) 
   The percentage of released amount of drug as a function of time is presented in 
Figure 14. In general, an increase in porosity and particle size fraction of the matrix 
compound used both enhance the drug release, as expected. This can be seen clearly 
with allopurinol, metronidazole, paracetamol and theophylline. The drug release 
behaviour of these tablets when a percolating matrix of SA is formed or when the 
porosity, using SA fraction of 149-297 µm, is 12 %, seems to follow the water 
solubility of the drug compounds. The unexpected higher released amounts of 
allopurinol and metronidazole might be due to homogeneity problems, leading to the 
variance in drug loading while mixing powders. 
   Interestingly, tablets containing acyclovir, which has quite a low water solubility 
and dissolution rate, displayed prolonged release properties only when SA fractions of 
< 53 µm or 53-149 µm were used. Even a decrease of porosity down to 12 % with the 
SA particle size fraction of 149-297 µm did not result in sustained release properties 
as with other compounds. Another anomalously behaving compound was 
salicylamide. Salicylamide tablets seemed to exhibit prolonged release in all of the 
formulations used despite the better water solubility and dissolution rate than 
acyclovir. In addition, the results were identical even if drug release promoting 
structures of the tablet, i.e. the utilization of SA fractions of 297-420 µm and 420-710 
µm, were used (Table 9). On basis of the characteristics of these compounds, this 
behaviour is unexpected and indicates that there could be some underlying 
interactions between salicylamide and SA affecting the drug release, which are much 
more complex than can be obtained from knowledge of solubility and dissolution rate 
of the drug compound or the structure of the matrix as Higuchi (1963) has proposed. 
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Figure 14. Drug release profiles of (a) acyclovir (AC), (b) allopurinol (AP), (c) 
metrodindazole (MD), (d) paracetamol (PC), (e) salicylamide (SC) and (f) 
theophylline (TF) as a function of time. The formulation in question, i.e. the porosity 
and particle size fraction of SA, is indicated on the right side of the figure. The 
standard deviation bars were left out for the sake of clarity (n=3-6). 
 
 
5.11 PLS analysis of drug release properties of the tablets (III) 
   The multivariate analysis was used in order to determine, whether the formulation 
parameters of drug compound properties were the most important features 
determining the drug release rate. The best PLS was achieved by using five principal 
components and observations from all the dissolution test time points. The variable 
exclusion was conducted on the basis of a coefficient plot and this resulted in a model 
having parameters R2(X) of 0.86, R2(Y) of 0.69 and Q2 of 0.65. In addition, the R2 
value at the time point of 480 min was improved from 0.74 to 0.80 when the 
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functionality of the model was tested, i.e. the test set was used instead of the training 
set. This was probably due to the rather large training set which results in a wider 
variance. Three observations were detected as outliers, which were three individual 
acyclovir containing tablets with SA fraction of 420-710 µm. These observations can 
be considered as extreme values and, therefore, this was accepted. In conclusion, the 
developed model can be regarded as satisfactory and it was used in the analysis. 
   The time point of 480 min was chosen for use in the subsequent experimets since it 
was one of the best modelled individual time points and it also represents well the 
median of the time points (Fig. 15). The order and magnitude of the important 
variables did not vary significantly even if other well modelled time points were used. 
The importance and extent of variables which remained after the creation of the 
model on the drug release at time point of 480 min are presented in the coefficient 
plot (Fig. 16). The interpretation of designations used in the coefficient plot is 
presented in Appendix 1. The height of the bar of the variable indicates its 
importance, i.e. the higher the bar, the more important the variable. Furthermore, 
variables with positive values correlate positively with the drug release and vice 
versa. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. The ability of PLS analysis to model (R2) (left bar at given time points) 
and to predict (Q2) (right bar at given time points) the amount of the drug release at 
given time points. 
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Figure 16. The coefficient plot showing the importance and effect of the variable at 
time point of 480 min. An increase of variable with a positive value will have a 
positive influence on drug release and vice versa. The height of the bar indicates the 
importance: the higher the bar the more important variable. Standard deviations are 
shown as error bars. 
 
 
5.12 The factors affecting the drug release (III) 
   By investigating Figure 16, it can be concluded that the most important variables 
affecting drug release are connected to the structure of the tablet and, in consequence, 
the formulation. The strongest positively affecting variables are the mass of the tablet, 
the value of CP, the mean particle size of SA and the porosity of the tablet. In 
contrast, compaction force has a strong negative impact on drug release. These 
findings were not surprising since in chapter 5.3 it was pointed out that the structure 
of the tablet is responsible for the drug release mechanism and rate can be controlled 
by means of particle size of SA and compaction. 
   In general, the impact of drug property based variables is not as high as compared as 
those of tablet structure and formulation variables. The physical drug particle 
properties affecting positively on drug release are surface energy and dissolution rate. 
The importance of surface energy is not surprising: particles having a high surface 
energy are indicated of a greater potential to interact with a large range of substances, 
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including water (Rupp et al. 2006). An increase in the mean particle size of the drug 
compound has a negative impact on the drug release rate, as predicted. All of these 
physical drug particle variables can be altered, e.g. by milling (York et al. 1998). 
   It can be summarised that the chemical properties affecting positively on drug 
release are connected directly or indirectly to water solubility and hydrophilicity. 
These drug release enhancing molecular properties represent an interaction potential 
with water by measuring not only truly hydrophilic areas, but also the amount of 
solvent accessible surfaces, both apolar and negatively charged. Furthermore, there 
are descriptors that are connected to diffusitivity which depict the flexibility of the 
molecule: the more flexible molecule, the more easily it diffuses. 
   Like drug release promoting descriptors, chemical properties that have a negative 
impact on drug release are mostly linked directly or indirectly to hydrophobicity. 
These descriptors represent the amount of the water repulsive hydrophobic areas, e.g. 
hydrocarbons having no highly electronegative atoms close to them, and even provide 
detailed parameters by describing the consistency of these areas and comparing their 
volume to hydrophilic volumes. In contrast to the drug release promoting negative 
charge, if there is an increase in the areas which are charged positively this seems to 
restrict drug release, since they might interact with the highly electronegative areas, 
i.e. the slightly negative oxygen atoms of SA (Fig. 1). 
 
 
5.13 Unexpected drug release rates of acyclovir and salicylamide (III) 
   As discussed in the previous chapter, the structural properties of the tablet have the 
greatest impact on drug release. Thus, the unexpected rapid drug release of acyclovir 
compared to its maximum water solubility may be explained by variations in the 
structure of the tablets which are due to the physical properties of the drug particles. 
The drug release controlling matrix was formed with acyclovir only when SA size 
fractions of < 53 µm and 53-149 µm are used (Table 9). When other SA fractions 
were used, this resulted in tablets where the percolating network consisted of both 
drug and matrix compound or of only drug compound. It appears that percolating 
networks made out of a hydrophilic drug compound almost act as a disintegrant 
enabling rapid drug release. This behaviour can also be seen with other drug 
compounds when the CP value is more than 1 and the porosity of the tablet exceeds 
20 %, with the exception of salicylamide (Table 9 and Fig. 14e). 
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   Tablets containing salicylamide exhibited almost identical drug release behaviour 
regardless of the structural changes of the preparation. This behaviour could be due to 
salicylamide's slightly larger particle size, though this is unlikely. The numerical 
values of descriptors, which are most important in order to interpret the interaction 
between salicylamide and SA, are presented in Table 10. It can be seen that 
salicylamide has the lowest values of drug release promoting descriptors TASA(jurs), 
which represents the sum of solvent-accessible surface areas of all apolar atoms, and 
BV21 -OH2, which stands for the best volume of hydrophilicity generated by a water 
molecule when it interacts with a target. 
   A further examination of Table 10 reveals that salicylamide displays high values in 
descriptors which have a negative impact on the drug release. Descriptor A is defined 
as a vector pointing from the centre of the hydrophobic domain to the centre of the 
hydrophilic domain, i.e. it defines the distance between the hydrophobic and 
hydrophilic areas. The descriptor integy moment (Iw1-7 -OH2) represents the 
unbalance between the center of mass of a molecule and the position of the 
hydrophilic regions around it. If the integy moment is high, the hydrated regions are 
clearly concentrated in only one part of the molecule. D12 -DRY represents the 
distances between the best two local minima of interaction energy when the 
hydrophobic probe interacts with a target molecule. Finally, descriptors D1 and 2 –
DRY represent the interaction between a hydrophobic probe and the target molecule, 
i.e. the magnitude of hydrophobicity.  
 
 
Table 10. Selected drug molecule descriptors of model compounds acyclovir (AC), 
allopurinol (AP), metrodindazole (MD), paracetamol (PC), salicylamide (SC) and 
theophylline (TF). 
Descriptor AC AP MD PC SC TF 
BV21-OH2 114.25 109.75 108.75 99.38 69.62 127.25 
TASA (jurs) 196.62 159.48 262.35 230.80 158.90 204.56 
A 1.66 0.71 2.73 2.40 4.27 1.17 
D1 -DRY 69.38 68.38 78.12 104.25 118.38 92.38 
D2 -DRY 51.25 49.12 44.25 61.62 71.25 58.75 
D12 -DRY 1.58 6.22 1.66 0.71 6.20 6.12 
Iw1 -OH2 0.07 0.05 0.06 0.11 0.23 0.04 
Iw2 -OH2 0.08 0.07 0.08 0.16 0.38 0.06 
Iw3 -OH2 0.13 0.11 0.11 0.28 0.63 0.08 
Iw4 -OH2 0.25 0.17 0.25 0.51 1.04 0.17 
Iw5 -OH2 0.40 0.22 0.48 0.76 1.41 0.41 
Iw6 -OH2 0.64 0.41 0.68 1.10 1.75 0.41 
Iw7 -OH 1.62 0.70 0.28 1.72 2.13 0.64 
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   If one tries to interpret these descriptors, it seems that salicylamide has a strong and 
large one-sided hydrophobic area. Indeed, by investigating all of drug compounds’ 
molecular structures (Table 8), it can be seen that they contain one or more of the 
following strongly hydrophilic groups: hydroxyl (acyclovir, allopurinol, 
metronidazole and salicylamide), amide (acyclovir, paracetamol, theophylline and 
salicylamide), nitrite (metronidazole) and primary and secondary amine (acyclovir, 
allopurinol and theophylline). Furthermore, these groups consist of highly 
electronegative atoms, mainly oxygen and nitrogen, i.e. they can affect the carbon 
atoms located next to them by attracting the electron cloud and this can make the 
carbon atoms more accessible to the water by generating slightly positive charge 
around the carbons. In most cases, these groups are located all around the molecule. 
However, in the case of salicylamide, hydroxyl and amide groups are located on the 
same side of the aromatic ring, leaving a hydrophobic area on the other side (Table 8). 
This unusual structural property explains the outcome of the descriptors: the 
hydrophobic aromatic ring contains poorly water accessible apolar atoms and this area 
is located at a great distance from the hydrophilic area. In conclusion, the descriptors 
correlate well with salicylamide's molecular structure and it can be assumed that the 
molecule's one sided hydrophobic area interacts with the surrounding hydrophobic 
starch acetate. This interaction seems to be a hydrophobic interaction, since it takes 
place only when there is an adjacent hydrophobic substance and it does not influence 
the water solubility of the salicylamide. Due to this proposed strong interaction, all 
tablets containing salicylamide exhibit almost identical drug release properties.  
 
 
5.14 The characterisation of model compounds (IV) 
   The suitability of the USP II paddle in vitro dissolution test was examined using two 
physicochemically different drug compounds. The physical characterization of SA, 
caffeine and riboflavin is presented in Table 11. It seems that the drug compounds 
have identical mean particle sizes. However, the particle size distribution of caffeine 
is notably wider, i.e. there are sufficiently large particles present which can be 
indicated by the values of D10% and D90%. Thus, as the powder for the tablet is 
mixed, riboflavin settles more uniformly onto the surfaces of the SA particles, 
resulting in the formation of a homogenous matrix when it is compressed into a tablet. 
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The particles of caffeine are more likely to be clustered throughout the matrix in SA 
tablets due to their wider particle size distribution. 
   In order to interpret the complex spectral data and consequently to generate accurate 
images from the maps obtained from the tablets’ cross-sections, it was important to 
find the characteristic peaks of all compounds that would remain constant, regardless 
of the sample preparation procedure. Freeze drying of caffeine did not change its 
crystal form, this being confirmed by DSC and FTIR (results not shown). The greatest 
and least overlapping single absorbance peaks for caffeine and SA were at 
wavenumber of 745 cm-1 and 1023 cm-1, respectively (Fig. 17). Unlike caffeine, the 
riboflavin polymorph changed during freeze-drying. This was unambiguously 
demonstrated by the changes in the DSC thermograms (results not shown) and FTIR 
spectra (Fig. 17). However, despite the polymorphic change of the compound, 
riboflavin’s characteristic peak, which is not dominated by the spectrum of SA, 
remained constant at a wavenumber of 1531 cm-1. For the FTIR mapping of starch 
acetate, the peak at the wavenumber of 1023 cm-1 was used. It can be seen from 
Figure 17 that there is some overlapping with the spectrum of riboflavin and SA at 
wavenumber of 1023 cm-1. Furthermore, there is another peak in the spectrum of SA 
at wavenumber of 1212 cm-1 which could be potentially used in the analysis. 
However, the results were similar with both wavenumbers (results not shown), but the 
peak at wavenumber of 1023 cm-1 was used due to its greater absorbance. 
 
 
 
Table 11. Physical characteristics of starch acetate, caffeine, riboflavin sodium 
phosphate and their mixtures. 
Material Particle size distributions (µm) Solubility in water 
 D10%a D50%a D90%a (mg/ml) 
Starch acetate 6 152 520 - 
Caffeine 2 20 215 15b 
Riboflavin  6 21 85 67b 
a D10%, D50%, D90% = The percentage of particles having a diameter under an indicated size. 
b Ph. Eur. 5th edition. 
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Figure 17. The spectra of caffeine (blue), freeze-dried (green) and untreated (purple) 
riboflavin, and SA (black). 
 
 
5.15 The visualisation of drug release during USP II paddle method (IV) 
   Light micrographs of tablet cross-section surfaces and FTIR maps of ATR-scanned 
areas for both drug compounds and starch acetate at different time points are shown in 
Figures 18 and 19 respectively. Each of the three pictures at the same time point 
correspond to each other. This can be demonstrated from Figure 18 at a time point of 
60 min. The visible micrograph is interpreted at this time point as follows: riboflavin's 
colour is yellow to red and the compound clearly stands out from the white matrix. 
The map for riboflavin and the light microscope picture of the cross-section both 
contain an island of drug compound at the same position, i.e. in the middle of the 
scanned area. In addition, there is a lack of matrix in the same place in the map for 
starch acetate at that same time point in support of this observation. 
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Figure 18. Light micrographs (a) and FTIR maps of riboflavin sodium phosphate (b) 
and starch acetate (c) of tablet cross-sections after immersion in dissolution medium. 
The extent of absorbance is indicated with the bar, where white denotes the highest 
and black the lowest absorbance. 
 
 
   In contrast to riboflavin, caffeine does not stand out from the matrix due to the 
similar appearance with starch acetate, as can be seen from Figure 19. It can be 
concluded that in the case of caffeine it would be almost impossible to distinguish the 
drug compound from the matrix without FTIR mapping. 
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Figure 19. Light micrographs (a) and FTIR maps of caffeine (b) and starch acetate (c) 
of tablet cross-sections after immersion in dissolution medium. The extent of 
absorbance is indicated with the bar, where white denotes the highest and black the 
lowest absorbance. 
 
 
   When comparing the differences between the maps of the two compounds (Fig. 18 
and 19), there appears to be more drug compound in tablets containing caffeine than 
riboflavin. The difference between the maps of caffeine and riboflavin might be due 
to the different particle size distributions of the drugs. It can be seen from Table 11 
that riboflavin contains of more uniform and smaller particles than caffeine, and so is 
able to produce a more homogenous distribution throughout the SA matrix. Caffeine’s 
particle size distribution is wider, and therefore, the obtained powder mixture and 
tablets are not as uniform, and they contain some large clusters of drug compound, 
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which affect the generation of maps. Another reason for the difference in maps is that 
at the chosen wavenumber, caffeine absorbs the infrared beam approximately 1.6 
times more efficiently than riboflavin. This affects the maps with caffeine standing 
out much more clearly, despite the scaling and practically identical degree of drug 
loading. 
   Drug compound diffuses out from the matrix as the liquid penetrates into the tablet 
and dissolves the drug. As the drug release from the matrix proceeds, FTIR mapping 
reveals that the number of clusters of drug compound starts to diminish and the 
clusters smear and stretch as a result of dissolution and diffusion. This can be seen in 
Figure 18 especially at the time points of 240 and 360 min, and from Figure 19 at the 
time point 480 min. Changes in the FTIR maps, which are attributed to dissolution 
and drug release, start to appear earlier with riboflavin than with caffeine, which is 
likely due to its higher water solubility (Table 11). Riboflavin diffuses out from the 
matrix more uniformly than caffeine, i.e. there are only a few clusters of drug at the 
end of the dissolution test, and in addition, it does not gather at the edges of the matrix 
at any time. However, there are clusters of riboflavin particles observed at 1440 min, 
though the amount is not substantial. This can be concluded from the map of the 
starch acetate at the same time point: there is no deviation in the structure of the 
matrix although there is some riboflavin present. These rather small particles of drug 
compound were trapped inside the SA matrix and therefore they could not diffuse out. 
Unlike riboflavin, caffeine seems to gather at the edges of the matrix, which can be 
seen in Figure 19 at time points of 360, 480 and 1440 min. 
 
 
5.16 Evaluation of functionality of USP II paddle method (IV) 
   It can be concluded by investigating equations (1) and (3) that several factors affect 
drug release by diffusion from the hydrophobic matrix in vitro, including the 
solubility and particle size of the drug compound, homogeneity of the content and 
pore structure of the matrix, and parameters of the in vitro test e.g. stirring speed and 
temperature of the dissolution bath. 
   Many authors have studied the hydrodynamics in the dissolution vessel during the 
USP paddle method test (Healy et al. 2002, Kukura et al. 2004, McGarthy et al. 2004, 
Baxter et al. 2005). These studies confirm that there is a low velocity domain of 
hydrodynamic flow at the bottom of the dissolution vessel. The drug release from the 
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lower part of the tablet which lies closest to the bottom surface of the dissolution 
vessel, is substantially inferior to other parts. Thus, drug potentially will not be 
released from the lower region of a matrix preparation immersed in the dissolution 
bath due to poor hydrodynamic conditions. It can be concluded that the factors 
promoting the drug release according to equations (1) and (3) are inadequate: there is 
no agitation of dissolution fluid between the tablet and dissolution vessel surface, 
which affects the concentration gradient, i.e. the driving force of solubility and drug 
release. The effect of this phenomenon can be seen from Figure 19, where caffeine is 
concentrated at the edge of the bottom part of the matrix, despite its optimal water 
solubility. This can be clearly seen at the time points of 360, 480 and 1440 min. The 
observation is not likely due to partition: the water soluble drug, caffeine, could not 
dissolve nor be absorbed in hydrophobic SA with as high ds as 2.7. In addition, only 
approximately 50 % of caffeine had been released at 1440 min (Fig. 20). In contrast, 
riboflavin is practically unaffected by the poor hydrodynamic conditions: there is no 
observation of a congregating effect in Figure 18. This is most probably due to its 
higher solubility and smaller particle size distribution (Table 11). Riboflavin dissolves 
well and consequently is released from the preparation even when the conditions for 
dissolution are not favorable. Figure 20 supports this result: over 80 % of riboflavin 
had been released after 1440 min. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20. Percentage of riboflavin (■) and caffeine (□) released as a function of 
time. Standard deviations are given as error bars (n=3). 
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5.17 Summary 
   The present study suggests that the powder blend organisation and consequent 
structure of the matrix tablet has an important role on drug release mechanism and 
rate. The structure of the matrix tablet can be controlled by altering the particle size 
fraction of the matrix forming hydrophobic excipient or making the tablet more 
porous by lowering the compaction pressure. It is possible to obtain an estimate of 
tablet structure if one combines carrier payload data with information about the 
fracture/yield strength. This is especially true if the estimation is related to the 
existence of an excipient matrix. When a hydrophobic excipient with an adequately 
small particle size fraction is used, it can form a percolating network within a matrix 
tablet. The consistency of the network matrix in the tablet is of major importance in 
determining the drug release mechanism and rate. A networking matrix of hydrophilic 
drug alone leads to immediate tablet disintegration and rapid drug release. Co-existing 
percolating networks of drug and excipient mean that there is surface erosion of the 
tablet and highly variable drug release. When the hydrophobic excipient is 
percolating, tablets maintain their shape and only crack during dissolution tests. 
Furthermore, tablet porosity affects also the drug release mechanism. In the mixtures 
examined here with increasing tablet porosities from 10% to 20 %, the difference in 
drug release was primarily the result of changes in relaxational component, and with 
higher porosities, due to the diffusional component. 
   Liquid penetration into the tablet is a prerequisite for the dissolution of the drug 
compound and its consequent release. However, in the case of tablets where the 
networking matrix is composed of a hydrophobic excipient, the penetrating liquid 
weakens internal bonds and initially this causes tablet expansion. After a certain 
period of time, the tablet expansion is transformed from tablet swelling into tablet 
cracking. The cracking increases the drug release rate by shortening the length of the 
diffusion path, increasing the effective surface area and lowering the degree of 
tortuosity. 
   Although the structure of the tablet has the greatest significance on drug release rate 
and mechanism, the properties of the drug compound cannot be overlooked. On basis 
of the results, it can concluded that in most cases, the drug release rate of structurally 
identical tablets follows maximum water solubility and solubility rates, of which the 
latter can be promoted traditionally by means of formulation, e.g. milling. However, 
the formation of matrix and the combined mechanism of drug release may be 
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extremely complicated and, therefore, a knowledge of maximum water solubility and 
dissolution rate cannot describe the entire process adequately. Although a drug 
particle appears to have sufficient water solubility and dissolution rate for the desired 
drug release profile, other properties, such as the magnitude and location of 
hydrophilic and hydrophobic areas, can cause major interactions with controlled 
release excipients which might not be beneficial to the drug release. These chemical 
molecular properties cannot be eliminated by means of traditional pharmaceutical 
processes and, thus, properties and nature of the drug particle in question need to be 
comprehensively characterized in order to achieve a successful outcome in the 
formulation task. 
   The drug release mechanism and rate is most often studied using standardized in 
vitro tests described by the Pharmacopoeias. The USP paddle method produces 
relevant data describing the drug release of prolonged hydrophobic tablets if the 
preparation consists of an extremely water soluble compound, such as riboflavin 
sodium phosphate, with a homogenous distribution within the matrix tablet. However, 
in the case of caffeine, which was a less water soluble compound and whose particle 
size distribution is wide and as a consequence the drug distribution is less 
homogenous, the in vitro test may not produce results with adequate relevance. The 
results obtained by utilization of Fourier transform infrared mapping in ATR mode, 
which is a method for distinguishing the drug substance from the matrix compound, 
revealed that caffeine was clearly concentrated at the bottom edge of the tablet in 
contact with the dissolution vessel, although the poor hydrodynamic properties of the 
USP paddle method were considered to play a large part in this observation. The 
results would suggest that the in vitro dissolution test should be chosen extremely 
carefully for prolonged release preparations or the existing test should be modified, 
especially, when the drug compound is not highly water soluble and the matrix is a 
hydrophobic polymer based tablet. 
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6 CONCLUSIONS 
 
   The present study has examined the methods which can be used to modify the 
structure of the starch acetate (ds 2.7) matrix tablet. Furthermore the impact of the 
structure on the drug release mechanism was determined and possible interactions 
affecting this mechanism were investigated. Finally, the suitability of USP II paddle 
apparatus was evaluated. Based on the results presented, the following specific 
conclusion can be made: 
 
1. The drug release mechanism and rate can be controlled by means of particle 
size distribution and compaction pressure when the SA with a degree of 
substitution 2.7 is used. When SA particles having a small particle size are 
used, the excipient can produce percolating network having drug release 
mechanism of diffusion. In addition, tablets consisting of both hydrophilic and 
hydrophobic matrices release their content by erosion and tablets having only 
hydrophilic matrix show rapid disintegration. For studied mixtures with 
increasing tablet porosities from 10% to 20 %, the difference in drug release is 
primarily the result of changes in the relaxational component, and with higher 
porosities, due to the diffusional component. 
 
2. Tablets are complex systems consisting of inter- and intra-particulate bonds, 
where the energy generated during compression is stored. The liquid 
penetrates into positions among the polymer molecules and reduces bonding 
forces and the stored energy releases resulting in crack formation. Crack 
formation shortens the length of the diffusion path and decreases the 
tortuosity, which promotes the liquid penetration and increases the drug 
release rate. 
 
3. The most important features affecting the drug release rate are formulation 
parameters responsible for the structure of the matrix. The drug compound 
properties, such as water solubility and dissolution rate, and factors which 
promotes these features become more important when the structure of the 
tablet is kept standardized. However, the interaction between a drug and 
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excipient arising from the molecular structures of both compounds may cause 
unexpected results in the drug release rate, which cannot be eliminated or 
overcome by traditional pharmaceutical processes, such as milling.  
 
4. The USP paddle method can be used in order to estimate the drug release 
properties of prolonged preparations in vitro and it produces reliable results 
especially with preparations containing extremely hydrophilic drug compound 
with homogenous distribution. However, its suitability may be questionable 
with preparations consisting of less hydrophilic compounds with uneven 
distributions. Since the preparations have non-optimal hydrodynamic 
conditions, the drug compound may congregate at the bottom of the 
preparation and this can lead to incorrect results. 
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APPENDICES 
 
Appendix 1 (Table) 
The list of formulation and drug property based parameters that were included in the 
final analysis. The most positively affecting parameters are placed at the top of the list 
and vice versa. 
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Appendix table 1. The list of formulation and drug property based parameters that 
were included in final analysis. The most positively affecting parameters are placed at 
the top of the list and vice versa. 
Parameter Designation 
Mass of the tablet TablMass 
Carrier payload CP 
Mean particle size of the SA d(0,5)SA 
Porosity of the tablet Porosity 
Surface energy of the compound (γSD) gSd 
Second best of three hydrophilic volumes of the molecule BV21 -OH2 
The maximum extension of molecule, when properly stretched (Elongation) Elon 
Critical packing CP(VolSurf) 
Drug loading of the tablet DLoading 
Dissolution rate of the drug compound Sol.rate 
Maximum solubility of the drug compound Cmax 
Fractional atomic charge-weighted negative surface area FNSA3 
Total apolar solvent -accessible surface area TASA 
Homogeneity of the powder Homogen 
Dipolemoment y Dipole mom 
Fractional charge-weighted negative surface area FNSA2 
Relative apolar solvent-accessible surface area RASA 
Relative negative charge solvent-accessible surface area RNCS 
Relative polar surface area RPSA 
Fractional atomic charge-weighted positive surface area FPSA3 
Dipolemoment x Dipole mom 
Hydrophobic regions D1-D2-DRYa 
Diffusitivity DIFF 
Local interaction energy minimal distances D12 -DRYb 
Mean particle size of the drug d(0,5)Drug 
Local interaction energy minimal distances D23 -DRYb 
Integy moment Iw1-Iw7c 
Amphiphilic moment  A 
Compaction force of the tablet CompForce 
aHydrophobic regions have been calculated using two different energy levels (-0.2 and -0.4 kcal/mol) 
bLocal interaction energy minima distances are calculated from three different minimal, although two 
of them were important enough to end up into model 
cIntegy moment has been calculated using seven different energy levels (-0.2, -0.5, -1.0, -2.0, -3.0, -4.0 
and -5.0 kcal/mol) 
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